Cerebral Magnetic Resonance Spectroscopy Biomarkers and Outcome in Perinatal Asphyxia by Chandrasekaran, M
1 
 
Cerebral Magnetic Resonance Spectroscopy 
Biomarkers and Outcome in Perinatal Asphyxia 
 
 
Dr Manigandan Chandrasekaran MBBS, MRCPCH, DCH 
Academic Neonatology 
Institute for Women’s health 
University College London 
London 
 
 
 
Supervisors:  Prof. Nicola Jayne Robertson 
 Prof. Gennadij Raivich 
 
 
 
Submitted to the University College London for the Degree 
of Doctor of Medicine 
 
2 
 
Declaration 
 
I, Manigandan Chandrasekaran, confirm that the work presented in this thesis 
is my own. Where information has been derived from other sources, I confirm 
that this has been indicated in the thesis. 
 
 
 
Signed:         Date: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Abstract 
 
Background: Neonatal encephalopathy is a common clinical condition 
affecting 2-3 per 1,000 neonates in the developed world. 10-15% of cases 
will die in the neonatal period. Therapeutic hypothermia has become the 
standard of care in the developed world for infants with moderate to 
severe neonatal encephalopathy only recently, after 2 decades of 
experimental and clinical studies. Approximately half the infants who 
receive therapeutic hypothermia stil l have an abnormal outcome. 
Research is now being focused on pre-clinical and Phase II clinical 
studies of drugs, which act synergistically or additively with therapeutic 
hypothermia. Magnetic resonance spectroscopy (MRS) techniques 
provide translational biomarkers, which may be used to speed up the 
development of safe and effective neuroprotective interventions. The 
precise relation between MRS and brain histology is unknown and it is 
unclear whether cooling itself alters the prognostic efficacy of MRS.  
Aim: (i) To explore the relation between MRS biomarkers and the degree 
of brain pathology observed in our pre-clinical piglet model of perinatal 
asphyxia; (ii) To assess the predictive value of MRS biomarkers in infants 
with neonatal encephalopathy 
Methods: In our piglet study, data from 2 large piglet asphyxia studies 
investigating neuroprotective agents were analysed. 1. The first was a 
study of Xenon-augmented hypothermia. Following transient hypoxia-
ischemia, 36 piglets were randomised into 4 groups (each n=9), with 
intervention from 2-26 h: Group (i) normothermia (38.5oC); Group (ii) 
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normothermia (38.5oC) + 24 h 50% inhaled xenon; Group (ii i) 24 h 
therapeutic hypothermia (rectal temperature (Trecta l) 33.5oC) or Group (iv) 
24 h 50% inhaled xenon +24 h therapeutic hypothermia (Trecta l 33.5oC). 2. 
The second was a study investigating Amiloride as a neuroprotective 
agent. Following transient hypoxia-ischemia, 18 male piglets (<24 h of 
age) were randomized to 2 groups (each n=9) (1) normothermia; or (2) 
2.5mg/kg of methyl isobutyl amiloride (MIA) at 10 minutes after 
resuscitation and 8 hourly thereafter.   
Both studies were performed on a Bruker 4.7 Tesla MR system. Following 
resuscitation after hypoxia-ischemia, proton (1H) magnetic resonance 
(MR) spectra were acquired with repetition time (TR) 5 sec, 128 summed 
transients, and echo times (TE) 25 ms, 144 ms, and 288 ms. (we 
measured the following peak area ratios: Lactate/N acetyl aspartate 
(Lac/NAA) and Lactate/Creatine (Lac/Cr) in both white matter and 
thalamus).  Phosphorus (31P) MR spectra were acquired from whole brain 
using single-pulse acquire with TR 10 s (we measured inorganic 
phosphate (Pi)/exchangeable phosphate pool (EPP = Pi + PCr + (2γ +β)-
NTP), NTP/EPP). Immunohistochemistry was performed on brain sections 
for activated Caspase 3, TUNEL positive cells and Iba I (activated 
microglia) to quantify cell death and microglial activation.  
For the clinical study, we assessed 45 infants (median gestational age – 
40 weeks) with moderate to severe neonatal encephalopathy admitted 
over a 3 year period to the neonatal unit at UCH. Their 
neurodevelopmental outcome was assessed at 18 months. 
Results: (i) Experimental Study - Early Biomarkers Early biomarkers 
(acquired between 2 and 4 hours after hypoxia-ischemia) in particular 
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thalamic Lac/NAA, predicted the 1H MRS area under the curve values 
from 0-48h and quantitative immunohistochemistry at 48 hours. Late 
Biomarkers: WM Lac/Cr at 40-48h after HI demonstrated the highest 
positive correlation with Tunel positive cell death (R20.98, p = 0.01) and 
NTP/EPP with microglial ramification (R20.68, p = 0.006); this correlation 
was present in both treated and untreated piglets. 
(ii) In the clinical study, deep gray matter Lac/NAA was the most accurate 
predictor of long term adverse neurological outcome following NE; 
importantly the predictive accuracy of Lac/NAA was unaltered by 
preceding therapeutic hypothermia. 
Conclusions: (i) Early thalamic Lac/NAA predicted the subsequent 
trajectory of energy disruption; this has importance in understanding the 
relevance of very early MRS studies in babies. White matter lactate/Cr at 
40-48h correlated best with quantitative immunohistochemistry (especially 
TUNEL positive cells) and this relationship was present with and without 
preceding therapeutic intervention. (ii) In babies with neonatal 
encephalopathy, the predictive accuracy of Lac/NAA was unaltered by 
therapeutic hypothermia.  
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1.1 Epidemiology 
General introduction 
Cerebral palsy (CP) remains the largest single cause of childhood disability in the 
developed world with a prevalence of 2 per 1000 live births (Surman, Bonellie et al. 
2006). Historically, the first clinical description of spastic diplegia was by William John 
Little, an orthopaedic surgeon who specialized in childhood deformities. He first 
presented a series of lectures titled Deformities of the Human Frame (Little 1843) 
and later presented a paper linking difficult labour, prematurity and neurological 
problems later in life (Little 1862). Since then, decades of debate have ensued on the 
exact relationship between hypoxia-ischemia (HI) and brain injury. It was not until the 
early 1950s that measures were undertaken to establish firm epidemiologic and 
physiologic relationships between neurologic abnormalities of childhood and the 
events of labour. New insights from research into the etiology of cerebral palsy have 
recently transformed the old concept that most cases of cerebral palsy begin during 
labour. 
Definitions 
The terms “asphyxia”, “hypoxia”, “hypoxemia” and “hypoxia-ischemia” have often 
been used interchangeably. It is essential to understand the exact definition of these 
words to establish the relationship with neurological outcome in later childhood. 
Tissue hypoxia is the central process, and it is defined as diminished oxygen delivery 
to the tissues. It is intracellular hypoxia, which initiates anaerobic metabolism, 
metabolic acidosis and results in cell death. The neonatal brain is very sensitive to 
the effects of tissue hypoxia. Tissue hypoxia can be produced either by hypoxemia, 
which is defined as decreased oxygen concentrations within the blood and/or 
ischemia, which is defined as decreased blood flow to the tissues. Asphyxia refers to 
impairment in blood gas exchange resulting in hypoxemia, hypercapnia and acidosis. 
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This definition of asphyxia was by a task force for the world federation of neurology 
group (Bax and Nelson 1993).  
In addition, other terms including neonatal encephalopathy (NE) and hypoxic-
ischemic encephalopathy (HIE) also need clear definition as often they have been 
used incorrectly. Neonatal encephalopathy is defined as a clinical syndrome of 
disordered neurological function in a term or near term infant in early neonatal period 
and is usually manifested by difficulties in initiating and maintaining respiration, 
depressed tone and reflexes, altered consciousness levels and commonly associated 
with seizures (Nelson and Leviton 1991). Neonatal encephalopathy may be 
associated with variety of causes including genetic, metabolic, infective conditions 
and others (Hankins and Speer 2003). However, HIE is one form of NE where there 
is strong evidence of intrapartum asphyxia resulting in neurologic depression with or 
without seizures. In the past, it was largely assumed that most cases of NE were due 
to adverse intrapartum events. However, the term NE is simply a clinical description 
of disturbed neurological function regardless of its etiology or pathogenesis. So the 
term HIE refers to the sub-set of cases of NE where there is evidence of a recent, or 
intrapartum hypoxia-ischemia as a cause. Hypoxic ischemic encephalopathy is 
associated with multiple factors including maternal, cord, placental and neonatal 
factors. It could be due to acute or chronic event.   
Incidence  
The incidence of NE reported from various studies ranges from 2 to 6 per 1000 live 
births (Brown, Purvis et al. 1974, Badawi, Kurinczuk et al. 1998, Ellis, Manandhar et 
al. 2000, Evans, Rigby et al. 2001). The incidence of HIE varies from 1 to 8 per 1000 
live births from various studies (Kurinczuk, White-Koning et al. 2010) 
There have been some difficulties in estimating incidence accurately from these 
studies. One of them is the use of several case definitions in the studies.  In addition, 
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some of them are hospital based and some are population-based studies. This is a 
problem because hospital based studies have higher incidence than population 
based studies as they are conducted in tertiary referral centres. The other issue is 
the time period of the study as most of the hospital-based studies are older than 
population based studies. There is a decrease in the incidence from 1970s through to 
1990s (Hull and Dodd 1992, Smith, Wells et al. 2000).  
Furthermore, the same denominator was not used in all studies, as gestational age 
was different in different studies. In addition to methodological differences, the basic 
data, which is from various part of the world, may not be applicable to the local 
population to estimate incidence. In a review of the relationship between NE and 
cerebral palsy in 2003, the American College of Obstetricians and Gynaecologists 
and the Academy of Pediatrics concluded that the best estimate of the incidence of 
NE comes from population data and was 1.9 to 3.8 per 1000 (American College of 
Obstetricians and Gynecologists 2002). Finally, based on population studies with 
similar inclusion and denominator criteria, Kurinczuk et al estimated the incidence of 
NE to be 3.0 per 1000 live births (95%confidence interval 2.7-3.3), incidence of HIE 
to be 1.5 per 1000 live births (95% confidence interval 1.3-1.7) (Kurinczuk, White-
Koning et al. 2010) 
Risk factors  
Risk factors for NE are diverse and identifying them helps us understand the 
pathogenesis and develop preventive strategies. There was a difficulty in identifying 
the risk factors, as there was no universally accepted case definition and no properly 
designed studies. Various intrapartum and antepartum risk factors are present in NE 
as demonstrated in the case control study from Western Australia (Badawi, 
Kurinczuk et al. 1998, Badawi, Kurinczuk et al. 1998). Intrapartum risk factors 
included maternal pyrexia, persistent occipito-posterior position and acute 
intrapartum events. In this study, around 30% of cases of NE are associated with the 
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evidence of intrapartum hypoxia (Figure 1.1) and the rest of the cases are due to 
other risk factors. This is very different to the case control study from Nepal, where 
around 60% of NE cases had evidence of intrapartum hypoxia (Ellis, Manandhar et 
al. 2000). Intrapartum risk factors from this study included non-cephalic presentation, 
prolonged rupture of membranes, cord prolapse and uterine rupture.   
 
Figure 1.1: Distribution of risk factors for neonatal encephalopathy. The Western 
Australia case control study (Badawi, Kurinczuk et al. 1998) Permission to reproduce this 
figure has been granted by BMJ Publishing Group Ltd. 
The role of NE and HIE in causation of cerebral Palsy 
Cerebral palsy (CP) is a group of disorders of the central nervous system manifested 
by aberrant control of movement or posture, present since early in life and not the 
result of recognized progressive disease. The Surveillance of Cerebral Palsy in 
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Europe (SCPE) agreed a similar definition (SCPE 2000). The key elements in this 
definition are: 1) Cerebral palsy is a group of disorders which are permanent but not 
unchanging; 2) The condition involves a disorder of movement and/or posture and of 
motor function; 3) The condition is due to a non-progressive interference, lesion or 
abnormality of the developing immature brain. It remains a common and disabling 
condition in which the diagnosis may not be confirmed until 5 years of age. It is well 
known for decades that children born preterm and low birth weight have increased 
risk of CP (Fawke 2007, Platt, Cans et al. 2007).  
Decades ago, when electronic fetal monitoring was first introduced, it was thought 
that intrapartum hypoxia-ischemia accounted for 50% of perinatal mortality and 
morbidity (Quilligan and Paul 1975). Subsequently, population based studies have 
demonstrated that intrapartum hypoxia-ischemia was present in small percentage of 
term infants who developed CP ranging from 8% in Australia and 28% in Sweden 
(Blair and Stanley 1988, Hagberg, Hagberg et al. 2001). The rate of CP has not 
decreased in the past 30 years (Figure1.2) despite the fall in the incidence of HIE, 
widespread use of electronic fetal monitoring and increase in caesarean section (Hull 
and Dodd 1992, Clark and Hankins 2003). Findings from a hospital based study from 
2 tertiary neonatal units, which included 351 term infants with neonatal 
encephalopathy presenting within 72 hours of age, demonstrated that events in the 
immediate perinatal period are most important in neonatal brain injury (Cowan, 
Rutherford et al. 2003). They defined intrapartum asphyxia as the presence of at 
least 3 of the following: (1) late decelerations on fetal monitoring or meconium 
staining, (2) delayed onset of respiration, (3) arterial cord blood pH< 7.1, (4) Apgar 
score < 7 at 5 minutes, and (5) multi-organ damage. On the basis of magnetic 
resonance imaging (MRI) within 2 weeks of birth or postmortem examination, 80% of 
the neonates with NE and asphyxia had lesions of the deep gray matter, cortex, or 
white matter consistent with an evolving hypoxic-ischemic insult and 69% of 
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neonates with only seizures within 3 days of birth had acute ischemic or hemorrhagic 
lesions (Cowan, Rutherford et al. 2003). 
 
Figure1. 2: Cerebral Palsy rates per 1000 live births 1970 – 2000 (Clark and 
Hankins 2003) Permission to reproduce this figure has been granted by Elsevier. 
 
Historically, the factors used to define perinatal asphyxia, such as meconium-stained 
amniotic fluid and Apgar scores, were not specific to the disease process leading to 
neurologic damage. When 110 term infants with severe metabolic acidosis were 
examined, it was concluded that even severe acidosis in umbilical cord blood is 
insufficient evidence of intrapartum hypoxia-ischemia profound enough to cause 
neurologic damage (Fee, Malee et al. 1990). From a population based study in 
Western Australia, there was no evidence of intrapartum hypoxia in over 70% of 
cases of newborn encephalopathy and that isolated pure intrapartum hypoxia 
accounted for only 4% of moderate to severe newborn encephalopathy (Figure 1.1). 
They further observed that intrapartum hypoxia might have been superimposed on 
preconceptional or antepartum risk factors with pre-existing insult in 25% of cases. In 
1988, Blair and Stanley reported similar results; in only 8% of all of the children with 
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spastic cerebral palsy was intrapartum asphyxia the possible cause of their brain 
damage (Blair and Stanley 1988).  It can also be stated with certainty that the 
pathway from an intrapartum hypoxic–ischemic injury to subsequent cerebral palsy 
must progress through NE and that HIE is but a minor component of the broader 
diagnostic category of neonatal encephalopathy.  
Since early 1990s, considerable efforts have been put into define the criteria to 
diagnose intrapartum hypoxia sufficient to cause CP. It was first proposed by The 
American College of Obstetricians and Gynecologists (ACOG) and the criteria were 
further refined by the International Cerebral Palsy Task Force Consensus Statement 
(MacLennan 1999). Again the criteria have again been reviewed and knowledge 
updated by the ACOG and American Academy of Pediatrics Task Force on Neonatal 
Encephalopathy and Cerebral Palsy (American College of Obstetricians and 
Gynecologists 2002). These statements emphasise the use of multiple criteria for the 
diagnosis (Table 1.1). The recent Swedish study suggests that an increasing number 
of term infants fulfil now the ACOG criteria of intrapartum-events severe enough to 
cause CP(Himmelmann, Hagberg et al. 2010). A recent systematic review on the 
association between intrapartum hypoxia-ischemia and NE at term reported the 
proportion of cerebral palsy associated with intrapartum hypoxia-ischemia was only 
14.5% (Graham, Ruis et al. 2008). From the same study, the incidence of an 
umbilical arterial pH <7.0 at birth was 3.7 per 1000 births and the incidence of HIE 
was 2.5 of 1000 live births.
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Essential criteria (must meet all four) 
1. Evidence of a metabolic acidosis in intrapartum fetal, umbilical arterial cord, or 
very early neonatal blood samples (pH <7.00 and base deficit ≥12 mmol/l) 
2. Early onset of severe or moderate neonatal encephalopathy in infants of 
≥34 weeks' gestation 
3. Cerebral palsy of the spastic quadriplegic or dyskinetic type 
4. Exclusion of other identifiable aetiologies such as trauma, coagulation 
disorders, infectious conditions, or genetic disorders 
 
Criteria that together suggest an intrapartum timing but by themselves are non-
specific: 
5. A sentinel (signal) hypoxic event occurring immediately before or during labour 
6. Sudden and sustained fetal bradycardia or the absence of fetal heart rate 
variability in the presence of persistent, late, or variable decelerations usually 
after a hypoxic sentinel event when the pattern was previously normal 
7. Apgar scores of 0–3 beyond 5 min 
8. Onset of multisystem involvement within 72 h of birth 
9. Early imaging evidence of acute non-focal cerebral abnormality 
 
Table 1.1: Criteria to define an acute intrapartum event according to the ACOG and 
International Consensus criteria(American College of Obstetricians and 
Gynecologists 2002) Permission to reproduce this table has been granted by Wolters Kluwer 
Health. 
The Apgar score was first proposed more than 50 years ago and has become a 
standard method of assessing the condition of a newborn infant at birth (Apgar 
1953). This assessment entails the scoring of 0, 1 and 2 on the five physiological 
characteristics: pulse rate, respiratory effort, colour, muscle tone and response to 
stimulation. A retrospective study of Apgar scoring in children with CP demonstrated 
that the predictive value of the score for CP is very low as 73% of children with CP 
had high score at 5 minutes of age and 83% of infants with low score at 10 minutes 
of age were free of major disability at early school age (Nelson and Ellenberg 1981). 
Assessment of the newborn within minutes of delivery, whilst a useful measure to 
alert the clinician to potential evidence of an intrapartum event, is not able to give 
prognostic information. 
The clinical picture of neonatal encephalopathy is graded according to Sarnat and 
Sarnat (Table 1.2)(Sarnat and Sarnat 1976). The risk of death or major disability in 
infants diagnosed with mild encephalopathy was 2%, moderate encephalopathy was 
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19% and severe encephalopathy was 63%(MP Collins 2002).  
 Mild  Moderate  Severe 
Level of 
Consciousness 
Hyperalert Lethargic Stuporose 
Neuromuscular 
Control 
   
           Muscle tone Normal  Mild Hypotonic Flaccid 
           Posture Normal Flexion Decerebrate 
          Tendon reflex Hyper-reflexia Hyper-reflexia Absent 
          Clonus Present Present Absent 
Pupils Dilated Constricted Poorly reactive 
Seizures None Common Frequent/intractable 
Moro Reflex Strong Weak/incomplete Absent 
Suck Reflex Normal/weak Weak/absent Absent 
Table 1.2: Grading of neonatal encephalopathy by clinical evaluation - 
modified(Sarnat and Sarnat 1976) 
Amplitude-integrated electroencephalogram (aEEG) monitoring with the cerebral 
function monitor (CFM) was first described almost 40 years ago (Maynard, Prior et al. 
1969). The aEEG allows continuous long-term monitoring of background activity and 
has been used in the care of neonates with encephalopathy as it has allowed early 
prediction of neurodevelopmental outcome, especially when used in conjunction with 
clinical neurological evaluation. In a recent meta-analysis, which included 8 studies, 
there was an overall sensitivity of 91% (95% CI 87-95) and a negative likelihood ratio 
of 0.09 (95% CI .06-.15) for aEEG tracings to accurately predict poor outcome in 
infants with HIE (Spitzmiller, Phillips et al. 2007). 
There were more findings in the follow up, population based study of term infants 
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with NE in Western Australia (Badawi, Felix et al. 2005). Nearly one out of every four 
term children with CP has a history of moderate or severe neonatal encephalopathy. 
Cerebral palsy in this context is more likely to affect males, to be severe, and to be 
accompanied by epilepsy, lack of speech, and severe cognitive impairment. 
Moreover, of those who go on to develop CP following neonatal encephalopathy, 
about one out of every five will die in the first 5 years of life. Infants born in 
developing countries have a high risk of intrapartum-related injury (Lawn, Kinney et 
al. 2009). Almost one quarter of the world’s 4 million annual neonatal deaths are 
caused by perinatal asphyxia and 99% of these deaths occur in low and mid-
resource settings (Lawn, Cousens et al. 2005).  
Summary 
The relationship between intrapartum hypoxia-ischemia, neonatal encephalopathy 
and cerebral palsy is more complex than that originally described by Little 150 years 
ago. The causal chain of events resulting in NE is complex, multifactorial and far from 
completely understood. Hypoxic–ischemic encephalopathy represents a small subset 
of neonatal encephalopathy and an even smaller contributor to cerebral palsy. 
Several promising lines of enquiry and hypotheses relating to potentially modifiable 
risk factors were generated by previous epidemiological studies although these 
studies are now well over a decade old and there have been substantial changes in 
clinical practice and clinical governance since their publication. Advances in magnetic 
resonance (MR) brain imaging have led to a much better understanding of the 
relationship between brain injury and the likely timing of the causal insult in the 
antepartum and peripartum periods (Cowan, Rutherford et al. 2003). Amplitude 
integrated EEG is becoming routine in clinical practice. All of these developments 
merit further investigation in appropriately sized population-based case–control 
studies. 
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1.2 Mechanisms of brain injury after hypoxia-ischemia 
Introduction 
Hypoxic-ischemic brain injury is a predominant form of all brain injury encountered in 
the perinatal period and it is a major cause of subsequent neurological disability in 
term infants. Research has provided much greater insights into the pathogenesis of 
hypoxic-ischemic brain injury in the foetus and neonate, over the last two decades 
through both clinical and animal experiments. Understanding these mechanisms help 
the clinician understand the potential for recovery and to work on potential targets for 
intervention.  
 
The Neurotoxic Cascade 
Excitotoxicity 
The principle process responsible for hypoxic-ischemic damage to neurons is 
excitotoxicity (Choi and Rothman 1990). Excitotoxicity refers to cell death mediated 
by excessive stimulation of extracellular excitatory amino acid receptors (Choi and 
Rothman 1990). Glutamate is a neuro-transmitter, present in excitatory presynaptic 
terminals throughout the brain.  There are three types of glutamate receptors: N-
methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methylisoazole-4- propionic acid 
(AMPA), and kainic acid (KA). Normally these receptors mediate physiologic 
excitatory effects of the glutamate. Under normal conditions, neuronal and glial re-
uptake pumps remove glutamate rapidly from the extracellular space before toxicity 
occurs (Schousboe 1981).  
 
In hypoxia-ischemia, early severe disruption of function in glutamate synapses was 
observed and the activity of these reuptake pumps was markedly reduced 
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(Silverstein, Naik et al. 1991, Tao, Lu et al. 2001). Abnormally raised levels of 
glutamate have been demonstrated in the brain following asphyxia in animal models 
and in the cerebrospinal fluid (CSF) of neonates following severe hypoxic-ischemic 
insult (Hagberg, Andersson et al. 1987, Johnston, Nakajima et al. 2002). A study 
using 1H-MRS (proton magnetic resonance spectroscopy) also demonstrated that 
glutamate levels were elevated in the brains of infants with severe hypoxic-ischemic 
encephalopathy (Pu, Li et al. 2000). The energy for these reuptake pumps is derived 
from the anaerobic metabolism of glucose (Magistretti, Pellerin et al. 1999). Severe 
hypoglycaemic episodes have been shown to result in increased levels of 
extracellular glutamate (Ichord, Northington et al. 1999). 
 
Further evidence for the involvement of excitatory neurotransmitters in perinatal brain 
injury comes from the observation that areas of the term neonatal brain susceptible 
to damage which include the putamen, thalamus and the peri-rolandic cerebral 
cortex, have the highest density of glutamate utilising synapses (Johnston 1995, Sie, 
van der Knaap et al. 2000). Also, neuroprotection seen with the use of glutamate 
receptor blockers when administered after termination of the insult supports the 
central role of glutamate in brain injury (McDonald, Silverstein et al. 1990).  The 
immature developing brain is far more susceptible to excitotoxicity than mature adult 
brain because of the sub unit compositions of the NMDA receptors expressed during 
development (Monyer and Seeburg 1993, Holmes and Ben-Ari 2001) 
 
Calcium influx 
Membrane depolarization, along with high levels of synaptic glutamate, produces 
maximal opening of the channels and flooding of calcium and sodium into 
neurons(Choi and Rothman 1990).Normally mitochondria buffer intracellular calcium. 
However, the calcium ‘overload’ causes mitochondrial dysfunction (Stout, Raphael et 
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al. 1998, Johnston, Nakajima et al. 2002). Calcium influx initiates multiple 
pathways(Cheung, Bonventre et al. 1986). It activates many different enzymes 
including lipases and proteases. Lipase activation results in breakdown of cell 
membranes and production of prostaglandins and leukotriens. Activation of 
proteases causes activation of the caspase cascade leading to cellular apoptosis. 
Oxygen free radicals are generated as well during this process through activation of 
nitric oxide synthase (NOS) and xanthine oxidase by excessive calcium(Volpe 2001). 
It also uncouples oxidative phosphorylation, resulting in energy (ATP) depletion.  
 
Free radical injury 
Reactive oxygen and nitrogen species are produced during hypoxia-ischemia and 
reperfusion following hypoxia-ischemia (Bagenholm, Nilsson et al. 1998). These 
species are highly reactive compounds which can generate more free radicals 
through interaction with cellular components. This causes peroxidation of fatty acids, 
which results in cell membrane injury and necrosis. Free radical also causes cell 
death by apoptosis through activation of the apoptotic gene(Blomgren and Hagberg 
2006). Following hypoxia-ischemia, the inhibition of neuronal nitric oxide synthase 
improved long-term outcome in neonatal rats (van den Tweel, Peeters-Scholte et al. 
2002). Furthermore, it has been demonstrated that neonatal mice lacking neuronal 
nitric oxide synthase have been shown to be less susceptible to hypoxic-ischemic 
injury(Ferriero, Holtzman et al. 1996). Also, melatonin, a neurohormone with potent 
anti-oxidant activity, has been shown to have neuroprotective action on rat brains 
following hypoxia-ischemia and reperfusion(Wakatsuki, Okatani et al. 2001). In 
addition, melatonin was also neuroprotective following excitotoxic brain injury in 
newborn mice (Husson, Mesples et al. 2002).  
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In summary, following hypoxia-ischemia, a cascade of neurotoxic events was 
initiated that centres on the excitotoxicity by glutamate which, along with a reduced 
membrane potential, act to open the NMDA receptor. This results in influx of calcium 
into the cells. This leads to further mitochondrial dysfunction and production of free 
radical species which results in cell death through apoptosis and necrosis (Figure 
1.3).  
 
Figure1.3: Summary of neurotoxic cascade (Johnston, Trescher et al. 2001) Hypoxic 
ischemia triggers opening of NMDA-type glutamate receptor-operated channels in 
the cytoplasmic membrane, allowing Ca to flood into the cytoplasm. Ca fluxed 
through NMDA channels can activate Ca sensitive enzymes such as nitric oxide 
synthase (NOS), producing the free radical gas nitric oxide (NO), which is toxic alone 
or when combined with superoxide ions to form even more toxic peroxynitrite. One 
target of NO and peroxynitrite is mitochondria, which generate their own supply of 
oxygen free radicals under hypoxic conditions. cytochrome c protein released from 
distressed mitochondria triggers the activation of cysteine-dependent aspartate-
directed proteases (caspases) such as caspase 3 that lead to fragmentation of DNA 
and many other actions. DNA fragmentation in turn can trigger activation of poly 
(ADP-ribose) polymerase (PARP), a nuclear enzyme that facilitates DNA repair. 
Oxidative failure from hypoxic ischemia combined with a reduction in NAD can further 
impair mitochondrial function and reduce energy needed to maintain membrane 
potentials. A fall in membrane potential leads to passive opening of NMDA channels, 
worsening and extending the excitotoxic cascade. Permission to reproduce this figure has 
been granted by Nature Publishing Group. 
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The role of inflammation 
Role of Cytokines  
One of the mechanisms of brain injury, following cerebral hypoxia-ischemia, is 
through activation of cytokines. Pro inflammatory cytokines are released in response 
to hypoxia-ischemia (Hagberg, Gilland et al. 1996, Savman, Blennow et al. 1998). 
Both interleukin1 beta (IL-1 β) and tumour necrosis factor-alpha (TNFα) have been 
shown to increase in the brain 4-6 h after the insult.  High levels of IL1, 6, 13 and 
TNFα, were seen in infants who later developed cerebral palsy(Nelson, Dambrosia et 
al. 1998). These cytokines including TNFα, IL-1β and interferon gamma (INFγ) have 
toxic effects on vulnerable oligodendrocyte precursors and on neurons resulting in 
brain injury(Volpe 2001). Further evidence for the role of these cytokines comes from 
experimental animal models. Treatment with interleukin receptor antagonist 
ameliorates brain injury following hypoxia-ischemia(Hagan, Barks et al. 1996, 
Hagberg, Gilland et al. 1996). In addition, it has been shown that deletion of IL- 18 
and IL-1β reduced brain injury following hypoxia-ischemia(Hedtjarn, Mallard et al. 
2005). Another group of cytokines (anti-inflammatory), including transforming growth 
factor beta1 (TGF-β1) and interleukin-10 (IL-10) are released following cerebral 
ischemia (Raivich, Jones et al. 1999). TGF-β1 inhibits the activation of brain 
microglia (Suzumura, Sawada et al. 1993), and inhibits the microglial production of 
neurotoxic molecules such as nitric oxide, superoxide and IL-1 (Vincent, Tilders et al. 
1997). In adult, application of TGF-β1 strongly reduces the infarct size in cerebral 
ischemia (Vincent et al 1997). Systemic administration of IL – 10 reduced the 
excitotoxic brain injury in newborn mice (Mesples, Plaisant et al. 2003). So it is 
critical in maintaining the balance between pro and anti-inflammatory cytokines for 
neuroprotection.   
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Role of Microglia 
Microglia are a sub-type of monocytes. They have specific roles in immune 
surveillance, cytokine production, antigen presentation, complement activation and 
phagocytosis within the developing central nervous system. Microglia are highly 
ramified cells in the resting state with a tertiary and quaternary branching structure 
which is integral to their role in immune surveillance (Raivich 2005).  In addition to 
the resting state, microglia can take on a deramified, amoeboid phagocytic 
phenotype when needed. Microglia are activated along with neutrophil infiltration, 
during cerebral hypoxia-ischemia and reperfusion (Hudome, Palmer et al. 1997). 
Activated microglia were observed from 4 hours after reperfusion and continued to 
increase over the next 48 hours (Bona, Andersson et al. 1999). Microglial cells 
release neurotoxic substances such as glutamate, cytokines, reactive oxygen and 
nitrogen species. Activation of microglia has been shown in animal models of 
excitotoxic and hypoxic-ischemic brain injury (Hagberg, Peebles et al. 2002). 
Minocycline, a second-generation tetracycline antibiotic reduces microglial activation 
(Zemke and Majid 2004) and prevents brain injury when administered prior to, or  
after hypoxia-ischemia (Arvin, Han et al. 2002).  
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1.3 Neuronal cell death in cerebral hypoxia-ischemia 
Introduction 
Cell death is a fundamental biological process that is relevant to normal histogenesis 
and also to the pathogenesis of tissue damage. It has physiological and pathological 
importance. Cell death was first classified into apoptotic or necrotic in 1970s, based 
on the appearances under the microscope. Necrosis is a rapidly occurring form of 
cell death that is common in the acute phases of severe cerebral insults and has 
been attributed, in part, to alterations in ionic homeostasis. In contrast, apoptosis is a 
delayed form of cell death that occurs as the result of activation of genetic and 
molecular mechanisms.  
 
Figure 1. 4: Cell death phenotypes in experimental neonatal HI brain injury 
(Northington, Chavez-Valdez et al. 2011) Various relationships between the classical 
and hybrid forms of cell death are suggested by their appearance on electron 
microscopy as represented by the arrows in the figure. Autophagocytic-appearing 
neurons with large numbers of cytoplasmic vacuoles, partially condensed nuclear 
chromatin, and preservation of cellular integrity are also found after neonatal HI. 
Autophagocytic cell death and apoptosis and possibly necrosis also exist on a 
continuum Permission to reproduce this figure has been granted by John Wiley and Sons. 
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With new insights from the research into the mechanisms underlying apoptosis, it is 
being recognized that both apoptosis and necrosis are likely part of continuum of cell 
death (Figure 1.4) with similar operative mechanisms rather than two different entities 
(Northington, Chavez-Valdez et al. 2011).  
 
Characteristics of necrosis 
Necrosis is a lytic destruction of individual or groups of cells. Necrosis is the major 
cell death in brain following acute neonatal HI injury in most animal models (Martin, 
Brambrink et al. 2000, Northington, Ferriero et al. 2001). Classical necrosis is defined 
by cytoplasmic swelling, nuclear dissolution (karyolysis), and is thought to be caused 
by rapid and severe failure to sustain cellular homeostasis. The process of necrosis 
involves damage to the structural and functional integrity of the cell plasma 
membrane and associated enzymes, abrupt influx and overload of ions, and rapid 
mitochondrial damage and energetic collapse (Martin, Brambrink et al. 2000, Golden, 
Brambrink et al. 2001). Subsequently, there is dissolution of organelles, rupture of 
the plasma membrane with leakage of cellular contents into the extracellular space, 
and random DNA degradation following histone proteolysis. Metabolic inhibition and 
oxidative stress from reactive oxygen species (ROS) are major culprits in triggering 
necrosis. Necrosis usually affects large groups of adjacent cells and is associated 
with inflammatory reaction. Recently, it has been shown that cell necrosis might 
involve the activation of specific signalling pathways or programs to result in cell 
death(Festjens, Vanden Berghe et al. 2006). 
 
Characteristics of apoptosis 
Apoptosis is an orderly process of dismantling of single cell or group of cells into 
components. Apoptosis as a mode of cell death following moderate hypoxic injury 
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has been shown in experimental models (Beilharz, Williams et al. 1995). It is one 
example of programmed cell death (PCD) that is ATP-driven and sometimes a gene 
transcription-requiring and caspase-dependent process(Tata 1966).  In most classic 
descriptions of apoptosis, the earliest changes occur within the nucleus. Cells 
undergoing apoptosis exhibit shrinkage of the cytoplasm and condensation of nuclear 
material into ``clumps'' (Walker, Harmon et al. 1988). Then, the nucleus undergoes 
fragmentation and the endoplasmic reticulum fuses with the plasma membrane 
forming vesicles and convoluting the surface of the plasma membrane. Finally, there 
is cellular fragmentation forming membrane-bound apoptotic bodies that contain 
intact cytoplasmic organelles and nuclear fragments, and these apoptotic bodies are 
subsequently phagocytosed by healthy neighbouring cells. The biochemical hallmark 
of apoptosis is the internucleosomal cleavage of DNA into double-stranded 
fragments, mediated by calcium and magnesium dependent endonuclease(Wyllie 
1980). There are key differences between apoptosis and necrosis morphologically 
(Table 1.3).  First, apoptotic cells exhibit loss of cytoplasm while necrotic cells have 
cytoplasmic swelling. Second, nuclear changes precede plasma membrane changes 
in apoptosis while the reverse is observed during necrosis. Third, apoptotic cells 
maintain plasma membrane integrity while necrotic cells undergo plasma membrane 
rupture. 
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Table 1.3: Characteristics of apoptosis and necrosis (Northington, Zelaya et al. 2007) 
Permission to reproduce this table has been granted by Elsevier. 
 
Component 
 
Apoptosis 
 
Necrosis 
 
Continuum 
 
Cytosol 
 
Cytoplasmic 
condensation and 
shrinkage, and plasma 
membrane blebbing; 
generally intact-
appearing 
mitochondria, though 
mitochondria may 
appear edematous 
Complete organelle 
disruption 
Variably swollen or 
ruptured organelles 
within a 
darkened/partially 
condensed cytoplasm 
with vacuolar changes 
in the perikaryon and 
occasional 
autophagocytic 
inclusions 
Cell membrane 
 
Cytoplasmic membrane 
fully intact 
Swelling and rupture of 
the cell membrane 
Intact cell membranes 
Nucleus 
 
Large 
spherical/globular or 
crescent-shaped 
chromatin clumps 
tightly compacted into a 
few (<3-4) fragments 
whose appearance is 
reminiscent of 
developmental 
programmed cell death; 
transformation of the 
nucleolus into separate 
granular masses, which 
unwind; preservation of 
nuclear membrane 
Watery, “clock face”–
appearing nucleus with 
widely dispersed and 
very small clumps of 
chromatin within an 
intact nuclear 
membrane  
Condensed, but not 
tightly compacted, 
chromatin clumps less 
regular in shape and 
divided into more 
fragments (>3) than 
that seen in apoptosis, 
with partially intact 
nuclear membrane 
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DNA fragmentation in apoptosis and necrosis 
Various biochemical markers have been used to classify cell death. The most 
extensively used marker for cell death is based on the integrity of nuclear DNA 
(Wyllie 1980). Genomic DNA degradation indicates an irreversible stage of cell 
death. In necrotic cells, DNA undergoes random fragmentation following histone 
proteolysis. However, histones remain intact in apoptotic cells, so DNA is cleaved 
into multimers of 180 to 240 base pairs (Wyllie 1980). Genomic DNA from necrotic 
cells exhibits a single vertical band on electrophoresis (``smear pattern''). But in 
apoptosis, genomic DNA will exhibit a ``ladder pattern'' on agarose gel 
electrophoresis (Wyllie 1980). However, biochemical markers of cell death vary from 
one cell type to another. In some cell cultures, apoptotic cell death occurs in the 
absence of demonstrable internucleosomal DNA fragmentation. The development of 
a technique to detect DNA fragmentation at the cellular level provided a new 
approach to diagnose cell death. This strategy is based on end-labelling single-
strand or double-strand DNA breaks using terminal deoxynucleotidyl transferase. 
This approach is called the terminal transferase-mediated dUTP nick-end labelling 
(TUNEL) method (Gavrieli, Sherman et al. 1992). This method is quite sensitive for 
detection of cells with DNA fragmentation, however, this does not discriminate 
among apoptotic and necrotic cell death (Grasl-Kraupp, Ruttkay-Nedecky et al. 
1995).  
 
Other forms of cell death 
Apoptosis is only one form of PCD. There are other forms: Caspase-independent 
apoptosis and non-apoptotic PCD (Lockshin and Zakeri 2002, Festjens, Vanden 
Berghe et al. 2006). Variants of classical apoptosis and non-classical apoptosis occur 
in brain during normal development and during pathogenesis, particularly following 
hypoxia-ischemia (Northington, Ferriero et al. 2001, Northington, Ferriero et al. 
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2001). Excitotoxins can induce non-classical form of apoptosis (Portera-Cailliau, 
Price et al. 1997). Autophagy is a highly regulated process that allows a cell to 
recycle its own cytoplasm and organelles. The degradation of organelles and long-
lived proteins is carried out by the lysosomal system. Autophagy is termed as type 2 
PCD. Presence of lysosomal vacuoles is the hallmark of autophagy. It is induced 
under starvation, differentiation, and normal growth control to maintain homeostasis 
and survival(Shintani and Klionsky 2004). Autophagy may have a significant role in 
pathogenesis of brain injury following HI (Ginet, Puyal et al. 2009). Inhibition of 
autophagy with 3-methyladenine up to 4 hours after focal ischemia is neuroprotective 
in p12 rats (Puyal and Clarke 2009). Conversely, induction of autophagy immediately 
following neonatal global HI in mice may be an endogenous neuroprotective 
mechanism (Carloni, Buonocore et al. 2008). 
 
Mechanisms underlying cell death 
Multiple apoptotic pathways have been shown to be involved in neonatal hypoxic-
ischemic cell death. Considerable data have accrued indicating that mitochondria 
participate in the critical effector stage of apoptosis. The mechanisms leading to 
secondary brain injury include excitatory amino acids, intracellular calcium, nitric 
oxide/reactive oxygen species, immuno-inflammatory activation, trophic factor 
withdrawal, and Bcl-2 family proteins. These perpetrators converge on mitochondria, 
and at a certain level of stress mitochondrial outer membrane permeabilization 
occurs, which results in irreversible cell death (Figure 1.5).
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Figure 1. 5: Mitochondrial outer membrane permeabilization AIF, apoptosis-inducing 
factor; CAD, caspase-activated Dnase; cyA, cyclophilin A; cytC, cytochrome C; 
BDNF, brain-derived neurotrophic factor; ic, intracellular; IGF-1, insulin-like growth 
factor 1; NF-kB, nuclear factor kappa B. (Hagberg, Mallard et al. 2009). Permission to 
reproduce this figure has been granted by Sage publications. 
The role of mitochondrial permeabilization 
Electron microscopy has shown swollen mitochondria with ruptured outer 
membranes with large amounts of calcium in the matrix often in neuronal cells early 
after neonatal hypoxia-ischemia (Puka-Sundvall, Gajkowska et al. 2000).  Increased 
mitochondrial permeability 0 to 1.5 hours and 6.5 to 8 hours after hypoxia-ischemia, 
indicating that the inner mitochondrial membrane was permeabilized to some degree 
after the insult, has been shown following reperfusion (Griffiths and Halestrap 1995). 
However, there is strong evidence that mitochondrial outer membrane 
permeabilization occurs during reperfusion in brain regions affected by hypoxia-
ischemia (Northington, Ferriero et al. 2001, Kroemer, Galluzzi et al. 2007). The 
extent of apoptosis-inducing factor translocation to the nucleus correlates with the 
morphological distribution of neuronal injury after hypoxia-ischemia (Zhu, Qiu et al. 
2003). Caspase inhibitors have also been shown to be protective in hypoxia-ischemia 
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(Cheng, Deshmukh et al. 1998). Apoptosis inducing factor deficiency confers 
considerable protection in mice subjected to neonatal hypoxia-ischemia (Zhu, Wang 
et al. 2007). 
 
Mechanisms of Mitochondrial Permeabilization 
There are two routes that lead to mitochondrial permeabilization (Scorrano, Nicolli et 
al. 1997). The first one is through the opening of the permeability transition pore (PT) 
in the inner membrane, and it is enhanced by cyclophilin D. The second one requires 
a direct permeabilization of the outer membrane by Bax/Bak and is considered to be 
cyclophilin D-independent (Figure 1.6).  It has been shown that ischemia induces 
opening of the cyclophilin D-dependent mitochondrial permeability transition pore in 
adult brain, leading to necrotic cell death (Basso, Fante et al. 2005). However, in the 
immature brain, Bax, rather than cyclophilin D, seems to be crucial for mitochondrial 
permeabilization. Bax is highly expressed in immature mitochondria. Bax 
translocates from cytosol to mitochondria after neonatal hypoxia-ischemia and Bax 
knockout mice are protected from hypoxic-ischemic brain injury (Gibson, Han et al. 
2001, Northington, Ferriero et al. 2001). Therefore, Bax-dependent mitochondrial 
outer membrane permeabilization is a critical event in neonatal brain injury. 
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Figure1.6: Mechanisms involved in mitochondrial permeability(Banasiak, Xia et al. 
2000) Permission to reproduce this figure has been granted by Elsevier. 
 
Genetic factors regulating cell death 
The Bcl-2 family is a growing group of proteins regulating cell death. More than 15 
Bcl-2 family members have been identified (Chao and Korsmeyer 1998). There are 
pro and anti-apoptotic proteins within the Bcl-2 family. It has been recognized for long 
time that pro- and anti-apoptotic Bcl-2 family proteins regulate Bax-dependent 
mitochondrial outer membrane permeabilization and are critical regulators of 
apoptotic cell death(Kroemer, Galluzzi et al. 2007). Most pro-apoptotic proteins (Bax, 
Bak, bok, Bad, Bim,Bid, and Puma) as well as anti-apoptotic Bcl-2 and Bcl-xL are 
highly expressed postnatally, followed by downregulation (except for Bcl-xL) with 
brain maturation (Shimohama, Fujimoto et al. 1998). Transgenic Bcl-xL 
overexpressing as well as Bad or Bim knockout mice are all resistant to postnatal 
hypoxia-ischemia(Parsadanian, Cheng et al. 1998, Ness, Harvey et al. 2006). In 
addition, the trophic factors insulin-like growth factor 1 (IGF-1), brain-derived 
neurotrophic factor (BDNF), and hexarellin, which at least partly act through 
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increasing anti- versus pro-apoptotic Bcl-2 family protein balance, all decrease 
downstream caspase activation and injury in the postnatal brain (Hagberg, Mallard et 
al. 2009). In summary, several Bcl-2 family proteins have an important role in 
neonatal brain injury. 
 
Cell death by apoptosis can be triggered by DNA damage and p53 is involved. p53 
functions in apoptosis or growth arrest and repair. Activated p53 binds the promoters 
of several genes encoding proteins associated with growth control and cell cycle 
checkpoints and apoptosis (eg, Bax, Bcl-2, Bcl-xL, and Fas) (Martin, Chen et al. 
2005).p53 deficiency protects against neuronal apoptosis induced by axotomy in vivo 
and may be important in delayed neurodegeneration following neonatal HI (Martin, 
Kaiser et al. 2001). Acute inhibition of nuclear factor kappa B (NF-κB) following 
neonatal HI prevents both nuclear and mitochondrial accumulation of p53 while 
providing significant sustained neuroprotection (Nijboer, Heijnen et al. 2008). 
 
Role of Caspases in cell death 
Caspases (cysteinyl aspartate-specific proteinases) are cysteine proteases; 14 
members have been identified so far (Wolf and Green 1999).There are three 
caspase-related signalling pathways have been identified that can lead to 
apoptosis(Figure 1.7); Firstly, the intrinsic mitochondria-mediated pathway is 
controlled by Bcl-2 family proteins. It is regulated by cytochrome c release from 
mitochondria, promoting the activation of caspase-9 through Apaf-1 and then 
caspase-3 activation (Li, Nijhawan et al. 1997). Caspase-3 activation results in 
proteolysis of essential cellular proteins, and can commit the cell to the morphological 
changes characteristic of apoptosis, including nuclear fragmentation (Wang, Karlsson 
et al. 2001). Secondly, the extrinsic death receptor pathway involves the activation of 
cell-surface death receptors, including Fas and tumour necrosis factor receptor, 
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leading to the formation of the death-inducible signalling complex (DISC) and 
caspase-8 activation that in turn cleaves and activates downstream caspases such 
as caspase-3, caspase-6, and caspase-7. Caspase-8 can also cleave Bid, leading to 
the translocation, oligomerization, and insertion of Bax or Bak into the mitochondrial 
membrane (Li, Zhu et al. 1998). The third pathway involves the activation of caspase-
2 by DNA damage or ER stress as a pre-mitochondrial signal (Robertson, Enoksson 
et al. 2002).  
 
Figure1.7: Death receptor signalling and programmed necrosis. DISC 5 ‘‘death-
induced signalling complex’’; FADD 5 Fas-associated death domain; HI 5 hypoxia-
ischemia; IKK 5 IkappaB kinase complex; JNK 5 c-Jun N-terminal kinase; NADPH 5 
nicotinamide adenine dinucleotide phosphate; NF-jB 5 nuclear factor kappa B; RIP1 
5 receptor interacting protein 1; RIP3 5 receptor interacting protein 3; ROS 5 reactive 
oxygen species; TNF 5 tumour necrosis factor; TRADD 5 TNF receptor-associated 
death domain; TRAF2 5 TNF receptor-associated factor 2. (Northington, Chavez-
Valdez et al. 2011) Permission to reproduce this figure has been granted by John Wiley and Sons 
 
Caspase-3 cleavage and activation occur in brain after HI in neonatal rodents after 
hypoxia in neonatal piglet (Cheng, Deshmukh et al. 1998, Delivoria-Papadopoulos, 
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Ashraf et al. 2008). Activated caspase-3 has been shown in human post-mortem 
brain tissue of full term neonates with severe perinatal asphyxia. Cerebroventricular 
injection of a pan-caspase inhibitor or intraperitoneal injection of a serine protease 
inhibitor 3 hours after neonatal HI in rat has neuroprotective effects (Cheng, 
Deshmukh et al. 1998).  
 
Excitotoxicity, nitric oxide and cell death 
As described previously, excitotoxicity and nitric oxide plays a major role in neuronal 
death after HI. In addition, NMDA/nitric oxide activates poly (ADP-ribose) 
polymerase, which depletes mitochondrial reduced nicotinamide adenine 
dinucleotide NAD(H) levels and triggers mitochondrial apoptosis-inducing factor 
release. N-methyl-D-aspartate receptor antagonists improve mitochondrial 
respiration, attenuate caspase-3 activation, and decrease brain injury after neonatal 
hypoxia-ischemia (Hagberg, Gilland et al. 1994). Furthermore, the brain protection 
provided by the nitric oxide synthase inhibitor 2-iminobiotin was also accompanied by 
near-complete inhibition of caspase-3 and reduction of apoptotic cell death (Peeters-
Scholte, Koster et al. 2002). 
Cell Surface Death Receptors 
Cell death can be initiated at the cell membrane by surface death receptors of the 
tumour necrosis factor receptor superfamily (TNFRSF). The signal for cell death is 
initiated at the cell surface by aggregation of the death domain containing members 
of this receptor family by their specific ligand. Clustering of the ligand on the target 
cell recruits Fas-associated death domain (FADD),a cytoplasmic adapter molecule 
that functions in the activation of the caspase 8-Bid pathway (Li, Zhu et al. 1998). 
Signalling for apoptosis then proceeds via the extrinsic or intrinsic pathway.  Blocking 
Fas death receptor signalling by either pharmacologic or genetic means affords 
protection in these models (Graham, Sheldon et al. 2004).  
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New concepts of cell death following hypoxia-ischemia 
In neurodegeneration, cell death exists as a continuum of necrosis and apoptosis at 
opposite ends of a degenerative spectrum with intermediate hybrid form manifesting 
in between them (Figure 1.4 and 1.7). This type of cell death is observed after 
hypoxia-ischemia, axonal trauma and excitotoxicity in brain. Evidence for the 
existence of an intermediate ‘‘continuum’’ form of cell death has been demonstrated 
by the co-expression of markers for both apoptosis and necrosis in neurons in the 
injured forebrain at 3 hours following HI in neonatal rat. It has been shown that under 
certain conditions, autophagy is also part of the complex continuum of 
neurodegeneration following neonatal HI in mice (Ginet, Puyal et al. 2009).  
 
It is clearly evident from the recent data that timing and energy state are critical 
variables in modulating autophagy or any other form of cell death following perinatal 
HI (Ferriero 2002). Crosstalk among multiple signalling pathways supports the 
concept of a cell death continuum. A fundamental cornerstone of the continuum is 
thought to be gradations in the responses of cells to stress. In addition, programmed 
necrosis is increasingly recognized as a key form of neurodegeneration and also lies 
along the apoptosis necrosis continuum (Northington, Chavez-Valdez et al. 2010). 
Necrostatin inhibits death domain kinase, which is the key intermediate in 
programmed necrosis. Necrostatin provides sustained neuroprotection following 
neonatal HI in mice (Northington, Chavez-Valdez et al. 2010).   
 
Knowledge of these pathways of cell death has lead to a very important discovery 
about gender specific cell death pathways. Male neurons die mainly through 
activation of an apoptosis inducing factor (AIF)-dependent pathway while female 
neurons preferentially release cytochrome c from mitochondria and die as a result of 
subsequent activation of caspase 3 (Du, Hickey et al. 2009). Gender influenced the 
neuroprotective efficacy of 2-iminobiotin treatment – which was neuroprotective and 
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reduced cytochrome c release and caspase activation only in females (Nijboer, 
Groenendaal et al. 2007). The glutamate antagonist dextromethorphan was 
protective against stroke in male but not female mice at 12 days of age - this 
supports the greater influence of the excitotoxic pathway in immature males (Comi, 
Highet et al. 2006).  
 
Conclusion 
In summary, neuronal degeneration in the brain exists as a continuum between 
apoptosis and necrosis. Hypoxia-induced neuronal apoptosis involves an ever-
growing broad range of biochemical and genetic mechanisms. Many upstream 
events (eg, excitatory amino acids, nitric oxide, nuclear factor kappa B, and Bcl-2 
family proteins) important in neonatal brain injury all contribute to mitochondrial 
stress during the post-hypoxia-ischemia phase and mitochondrial outer membrane 
permeabilization will occur, leading to irreversible cell death. 
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1.4 Animal models of Hypoxia-ischemia 
Animal models have significantly contributed to our understanding of HIE in term 
newborn infants. The underlying pathophysiology of HIE is difficult to study in 
humans, therefore much of our knowledge of hypoxia-ischemia comes from animal 
studies. The first use of an animal model in the study of perinatal asphyxia was in 
1813, when LeGallois compared the newborn rabbit’s breathing with the adult animal 
after submersion (LeGallois 1813). He found that the respiratory efforts of newborn 
rabbits lasted much longer than adult animals. Subsequently, the relative resistance 
of newborn animal to asphyxia, when compared to adult animal, has been 
demonstrated in many species (Bert 1870, Britton and Kline 1945, Stafford and 
Weatherall 1960). Observations have also been made that males are less resistant 
than females, high temperature reduces resistance as does thyroxin, insulin injection, 
or adrenalectomy (Britton and Kline 1945). Very few animal species have escaped 
study, as observations have been made on the rat, cat, dog, rabbit, guinea pig, 
mouse, pig, sheep, monkey, baboon, and even bats. 
Several areas related to perinatal asphyxia have been studied in animal models. The 
effects on glucose metabolism and cerebral blood flow by asphyxia have been 
studied in a dog model (Duffy, Cavazzuti et al. 1982). They found that glucose use 
was highest in brainstem structures and lowest in white matter regions. A rat model 
described by Rice and Vannucci, has been widely used to assess the biochemical 
and molecular changes occurring in the neonatal brain as a consequence of 
asphyxia (Rice, Vannucci et al. 1981). The model is described as a one of 
moderately hypoxic ischemic encephalopathy, produced by unilateral carotid artery 
ligation followed by 8% 02 breathing at 37oC. Changes in 31P nuclear magnetic 
resonance, metabolic rate, cerebral blood flow and EEG have been studied in the 
beagle puppy (Ment, Stewart et al. 1988). In sheep model, it has been demonstrated 
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that pre-treatment of lambs with superoxide dismutase and catalase was 
neuroprotective following asphyxia (Vannucci 1990), thus explained the role of free 
radicals in brain injury.  Evidence of glutamate involvement in the pathogenesis of 
brain injury in hypoxia-ischemia comes from the studies performed in 1-day-old 
Sprague-Dawley albino rat pups (Schor 1988).  
Two distinct patterns of brain injury have been described experimentally; acute total 
asphyxia and chronic partial asphyxia. Acute total asphyxia was induced in near term 
monkeys by detaching the placenta at hysterotomy (Ranck and Windle 1959). Eleven 
to 16 minutes later the fetuses were delivered from their membranes and 
resuscitated. Patterns of symmetrical injury to the ventral posterior nuclei of the 
thalamus, putamen and globus pallidus in the brain were found after euthanasia. 
These patterns were a very similar topographical distribution to that seen in infants 
with basal ganglia and thalamus injury following for example a sentinel event. In 
contrast to acute total asphyxia, eight Rhesus monkeys were studied following 
prolonged partial insult (Brann and Myers 1975). Intrauterine asphyxia was produced 
in the pregnant term monkey by breathing halothane of a high enough concentration 
to cause a significant drop in mean blood pressure in the mother and each fetus was 
exposed to asphyxia for between 1 and 5 hours. At the end of the period of asphyxia, 
each fetus was delivered surgically and resuscitated. Seven showed a prolonged 
time to first gasp until they began breathing spontaneously. Examination of brain 
after euthanasia showed focal cortical injury with a predominance in the posterior 
parietal parasagittal regions. These findings are very similar to the pattern of injury in 
newborn infants who have experienced chronic partial asphyxia.  
Physiological, neurobiological, and pathological issues are very important when 
considering the relevance of experimental animals as models for brain injury in 
human newborn infants. The piglet models have been used to study hypoxia-
ischemia by many researchers. In contrast to the newborn rodent, the percentage of 
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adult brain weight at birth in piglets is much closer to human (Dobbing and Sands 
1979). In addition, the body size of the piglet and chest and cranial geometries, 
anatomy and physiology of the cardiovascular and pulmonary systems, as well as the 
cortical and basal ganglia topology are much more similar to human infants (Martin, 
Brambrink et al. 1997, Zhengyu, Zhimou et al. 2010). The basal ganglia particularly 
putamen and somatosensory systems, including primary somatosensory cortex and 
ventrobasal thalamus, are selectively vulnerable in this model following hypoxia- 
ischemia similar to newborn infants (Martin, Brambrink et al. 1997). Also, It has been 
shown that piglets and humans are comparable at birth regarding brain maturation 
(Grate, Golden et al. 2003). This model has also been used to study MRI and MRS 
effects following hypoxia-ischemia (Thoresen, Penrice et al. 1995, Penrice, Lorek et 
al. 1997, Munkeby, De Lange et al. 2008) 
In summary, animal models of perinatal asphyxia are not ideal and will always be an 
approximation to the clinical situation. However, they have remarkable similarities to 
our current understanding of the human condition. The relevance of the animal model 
must be appreciated in the context of human pathobiology of the model compared to 
that of the human term newborn. We used piglet asphyxia model for our research 
because of the similarities of piglet brain to human one as mentioned above. Finally, 
animal models are essential for identifying relevant injury related mechanisms of HIE 
and for testing preclinical efficacy of therapeutics.  
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1.5 Patterns of brain injury in hypoxia-ischemia 
Introduction 
Neonatal MR imaging is invaluable in assessing the term newborn with hypoxia-
ischemia. Magnetic resonance imaging provides detailed information about the 
pattern of lesions following perinatal brain injury and may provide excellent 
predictions of outcome. Patterns of brain injury are dependent on the severity and 
duration of the HI insult. In 1972, two patterns of perinatal brain damage was first 
described in an experimental model of primate foetuses, an acute and total hypoxic-
ischemic event produced cerebral injury largely affecting the deep gray matter 
structures (basal ganglia) and prolonged but partial hypoxic-ischemic insult produced 
a diffuse injury to the cerebral cortex and subcortical white matter, with significantly 
less injury to the basal ganglia and brainstem than is seen in the setting of acute 
profound asphyxia(Myers 1972). Since then, many researchers have described the 
patterns of brain injury in term newborn infants with HIE.  
Deep gray matter pattern 
This pattern, also called the basal ganglia and thalamus (BGT) pattern, is the most 
common pattern seen in infants with HIE(Martinez-Biarge, Diez-Sebastian et al. 
2010). The areas affected in this pattern include ventrolateral thalami and posterior 
putamen and peri-rolandic cortex. These deep nuclear structures are very 
susceptible to acute perinatal hypoxic-ischaemic injury because of their high 
metabolic rate and high concentration of NMDA receptors. This pattern is seen 
following ‘acute near total asphyxia’ (Pasternak and Gorey 1998). Often there has 
been an acute sentinel event like a ruptured uterus, placental abruption or a 
prolapsed cord (Okereafor, Allsop et al. 2008). Injury to brainstem and hippocampus 
has also been associated with this pattern.  
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The intensity of resuscitation and the severity of encephalopathy are associated 
strongly with the basal ganglia/thalamus predominant pattern (Sie, van der Knaap et 
al. 2000, Miller, Ramaswamy et al. 2005).  Basal ganglia and thalamic lesions were 
classified into mild, moderate and severe lesions depending on their extent of injury 
as shown in Figure 1.8(Okereafor, Allsop et al. 2008). Mild lesions are focal and 
subtle abnormalities in the basal ganglia and thalamus. Moderate lesions are usually 
multifocal lesions involving several regions of the basal ganglia. Severe lesions 
involve widespread abnormalities involving all BGT structures. 
 
Figure1.8: Axial T1-weighted images showing basal ganglia and PLIC 
abnormalities(Martinez-Biarge, Diez-Sebastian et al. 2010) Top row: A, mild basal 
ganglia–thalamic (BGT) lesions (arrow); B, moderate BGT injury (arrows); C, severe 
BGT abnormalities (circled).Bottom row: A, normal signal intensity (SI) in the 
posterior limb of the internal capsule (PLIC) (arrow); B, equivocal, asymmetrical and 
slightly reduced SI in the PLIC (arrow); and C, abnormal, absent SI in the PLIC 
(arrow) Permission to reproduce this figure has been granted by Elsevier. 
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Severe BGT lesions are often associated with the injury to the posterior limb of the 
internal capsule (PLIC). The internal capsule carries the major motor and sensory 
pathways to and from the cortex and the spinal cord. In addition, fibres from the 
thalamus also pass through it connecting to most regions of the cortex. It myelinates 
around term age, and is therefore a marker of maturation that is easily identifiable on 
MRI (Cowan and de Vries 2005). The internal capsule is divided into three main 
regions: (1) the anterior limb (ALIC) is the portion between the lentiform (lenticular) 
nucleus and the head of the caudate nucleus; (2) the posterior limb (PLIC) is the 
portion separating the lentiform nucleus from the thalamus; and (3) the genu is the 
portion at the junction of the above two parts. Myelination starts from the posterior 
limb around term gestation and progresses rostrally, complete full internal capsule by 
6 – 8 months. It is very susceptible to injury at this stage of development.  Depending 
on the myelination of PLIC, seen on MRI, it can be classified into normal, equivocal 
and abnormal. A normal PLIC is myelinating at term age and on MRI is seen as high 
signal on T1 weighted images and low signal on T2 weighted images. An abnormal 
PLIC has loss or reversed signal intensity on T1 and T2 weighted images (Figure 
1.8). Equivocal PLIC has reduced or asymmetrical signal intensity. 
Several studies demonstrated that BGT lesions and abnormal PLIC are associated 
with adverse neurodevelopmental outcome. Infants with moderate to severe BGT 
lesions will have a range of adverse outcome including CP, seizures, cognitive 
impairment, feeding problems, speech and language problems, visual and hearing 
impairment. Cerebral palsy was the outcome observed in 10 -15% in infants with mild 
BGT lesions, 60 – 75% in moderate BGT lesions and 98% in severe BGT 
lesions(Martinez-Biarge, Diez-Sebastian et al. 2010).  Around 20-30% of infants with 
HIE die in the neonatal period and 15-20% of children may die in the first 2-3 years. 
Around 50% of infants with brainstem lesions died in the neonatal or infant 
period(Martinez-Biarge, Diez-Sebastian et al. 2010). The signal intensity of the PLIC 
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is the best predictor of the ability to walk at 2 years (Martinez-Biarge, Diez-Sebastian 
et al. 2010).  
Watershed predominant pattern  
This pattern is often seen following ‘prolonged partial asphyxia’. The vascular 
watershed zones, between anterior–middle cerebral artery and posterior–middle 
cerebral artery are involved, affecting white matter (Figure 1.9). This is also termed 
as parasagittal cerebral injury or border zone injury. The lesions can be unilateral or 
bilateral, posterior and/or anterior. It is also more common after hypotension, 
infection and hypoglycaemia, all of which may be associated with a more protracted 
course. The injury comprises cortical necrosis involving the immediately subjacent 
white matter with characteristic distribution, encompassing the parasagittal, 
superomedial areas of the convexities bilaterally. Later MRI may show cystic 
evolution, but more often atrophy and gliotic changes are noted. Another vulnerable 
area for ischemic cerebral injury is at the depth of the sulci as the vessels bend 
acutely at the cortical-white matter junction(Takashima, Armstrong et al. 1978). This 
area represents “a border zone within a border zone”. Therefore cerebral injury is 
more severe in the depths of the sulci.  
Neurological signs in infants with this pattern may be mild and delayed (Sato, 
Hayakawa et al. 2008). They may not meet the criteria for HIE. Severe motor 
problems are uncommon in these infants. Commonly they have cognitive 
impairments including memory deficits, behavioral problems, or visual- perceptive 
dysfunction (Miller, Newton et al. 2002, Marlow, Rose et al. 2005). These cognitive 
deficits often result in delayed school-readiness and a need for additional school-age 
interventions. These cognitive deficits are not observed at 12 months of age, so later 
assessment of these infants is necessary. 
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Figure1.9: Full-term infant with watershed pattern of injury(de Vries and 
Groenendaal 2010)Loss of cortical ribbon is noted on the T2weighted image, and the 
corpus callosum appears to be swollen with increased signal intensity. Permission to 
reproduce this figure has been granted by Springer. 
Other patterns  
There are several other patterns of brain injury, which has been demonstrated in 
infants with hypoxia-ischemia. One of them is severe involvement of the subcortical 
white matter and cortex, with relative sparing of the immediate periventricular white 
matter and central grey matter. This is uncommon, and referred to as the ‘white 
cerebrum’, as diffusion weighted imaging (DWI) shows an almost completely white 
cerebrum, contrasted to a normal looking cerebellum (Vermeulen, Fetter et al. 2003). 
This condition tends to be fatal, and muticystic encephalomalacia will develop in 
surviving infants. Another pattern of brain injury consists of lesions restricted to the 
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periventricular white matter, similar to punctate white matter lesions in the preterm 
infant (Li, Chau et al. 2009).  
In summary, there has been tremendous development of MRI techniques over the 
last few decades. Magnetic resonance imaging can help in detecting different 
patterns of brain injury in (full-term) human neonates following HIE and is thus helpful 
in predicting neurodevelopmental outcome. 
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1.6 Energy changes after hypoxia-ischemia, 
secondary energy failure and Neuroprotection 
 
Introduction 
Magnetic resonance spectroscopy (MRS) has been used to study brain energy 
metabolism. phosphorus-31 (31P) and proton (1H) MRS have provided extensive 
information on cerebral energy metabolism during the evolution of brain injury 
following hypoxia-ischemia in the newborn infant (Azzopardi, Wyatt et al. 1989), 
neonatal rat (Blumberg, Cady et al. 1997) and the newborn piglet (Lorek, Takei et al. 
1994).  
Initial energy changes 
During a hypoxic-ischemic insult, there is a profound failure in cerebral energetics 
which resolves rapidly with resuscitation and reperfusion. Severe hypoxia-ischemia 
rapidly results in cessation of cerebral oxidative metabolism, accumulation of 
cerebral lactate and rapid depletion of adenosine tri-phosphate (ATP).  This decrease 
in ATP triggers a series of additional mechanisms that begin with failure of the ATP– 
dependent Na/K pump (Volpe 2001) (as discussed above).  Increased lactate occurs 
which is due to reduced oxygen supply resulting in decreased oxidative 
phosphorylation, causing enhanced glycolysis via the Pasteur effect. Initial lactate 
accumulation could be beneficial as it can act as a fuel and leads to generation of 
ATP from phosphocreatine (PCr)(Schurr 2006). However, severe tissue acidosis, 
which develops later, results in neuronal injury.  
Delayed or Secondary energy failure 
Initial energy changes noted during HI (31P MRS) return to normal levels after 
resuscitation in human infants (Hope, Costello et al. 1984, Lorek, Takei et al. 1994). 
However, several hours later, there follows a progressive decline in phosphocreatine 
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(PCr) and ATP, increase in inorganic phosphate (Pi) associated with a rise in lactate 
despite adequate resuscitation (Hope, Costello et al. 1984, Cady, Amess et al. 
1997)(Figures1.10, 1.11 and 1.12). These changes were termed delayed or 
secondary energy failure (SEF) to distinguish them from the primary energy failure 
that occurs during the acute hypoxic-ischemic insult. This SEF was observed only in 
infants with adverse outcome (Azzopardi, Wyatt et al. 1989). Thus, SEF was 
consequential to a pathological mechanism initiated by intrapartum HI or/and 
reperfusion.  
 
 
 
Figure1.10:31P spectrum from a control animal(Lorek, Takei et al. 1994) 1, 
phosphoethanolamine; 2, phosphocholine; 3a and b, Pi components; 4, phosphotidyl 
ethanoiamine; 5, phosphotidyl choline; 6, PCr; 7, γ-NTP; 8, α-NTP; 9, NAD and 
NADH; 10, uridine diphosphate sugars; 11, β- NTP. Permission to reproduce this figure has 
been granted by Nature Publishing Group. 
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Figure1.11: 31P spectrum from an animal, acquired at 46 hours after 43 minutes of 
HI. (Lorek, Takei et al. 1994)  Permission to reproduce this figure has been granted by Nature 
Publishing Group.  
Explanations for the delayed rise in cerebral lactate include inhibition of mitochondrial 
respiration or irreversible mitochondrial damage. Increased lactate correlate closely 
with falling nucleotide triphosphate (NTP)/exchangeable phosphate pool 
(EPP=Pi+PCr+NTP), and a possible explanation for this is that a fall in ATP 
concentration is required before the glycolytic enzymes phosphofructokinase and 
pyruvate kinase are significantly activated (Penrice, Lorek et al. 1997). Another factor 
to the delayed rise in lactate could be the removal of dead or dying cells by 
phagocytosis. The activation of human monocytes and macrophages enhances 
glycolysis leading to increased lactate production (Lopez-Villegas, Lenkinski et al. 
1995).
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Figure1.12: Representative 1H MRS brain spectra from a control infant and 2 
neonates with neonatal encephalopathy (Cheong, Cady et al. 2006). This was 
acquired between 2 and 4 days of age from an 8-mL voxel centred on the thalami by 
using PRESS (TE,270 ms; and TR, 2 seconds). The dashed lines are the spectrum 
analysis Lorentzian profiles fitted to the peaks. A, Control; B, Normal/mild outcome; 
C, Severe/fatal outcome. Permission to reproduce this figure has been granted by American 
Society of Neuroradiology.  
The biphasic decrease in NTP/EPP and reciprocal increase in brain lactate during 
and following a transient hypoxic–ischaemic insult are shown in figure 1.13.The 
mechanisms behind the progression from primary energy failure to secondary energy 
failure are those involving excitotoxins which results in cell death as explained above. 
In addition, the severity of secondary energy failure depends on the severity on 
primary insult (Lorek, Takei et al. 1994). The knowledge from these studies provided 
a basis for the realization that rescue treatment after hypoxia-ischemia may reverse 
or ameliorate SEF. Experimental studies with moderate hypothermia and other 
therapeutic agents soon followed (Thoresen, Penrice et al. 1995).  
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Figure1.13: The biphasic pattern of energy failure associated with a transient HI 
insult(Kelen and Robertson 2010). 31P MRS (top) and 1H MRS (bottom) in the UCL 
piglet model. 31P MRS: nucleotide tri-phosphate (NTP)/exchangeable phosphate pool 
(EPP=Pi+PCr+NTP) is shown on the y axis. The change in NTP/EPP during transient 
hypoxia–ischaemia (HI), resuscitation, the latent phase (period between the recovery 
from acute HI and the evolution of secondary energy failure (SEF)) and SEF itself are 
shown. 1H MRS: lactate/N acetyl aspartate (NAA) is shown on the y axis. The change 
in Lac/NAA during transient HI, resuscitation, latent phase and SEF are shown. 
Permission to reproduce this figure has been granted by Elsevier.  
Therapeutic hypothermia 
Experimental and clinical data indicate that induced hypothermia reduces cerebral 
hypoxic-ischemic injury. A series of large randomized clinical trials have now shown 
that moderate hypothermia improves neurological outcome at 18 months in infants 
with HIE (Gluckman, Wyatt et al. 2005, Shankaran, Laptook et al. 2005, Azzopardi, 
Strohm et al. 2009).  Meta-analysis of all trials with 18 months of follow-up suggests 
a number needed to treat of approximately 9, with a relative risk for death or disability 
of 0.81 (95% confidence interval, 0.71–0.93; p < 0.002) (Edwards, Brocklehurst et al. 
2010). Therapeutic hypothermia is now widely offered to infants with NE in developed 
countries (Kapetanakis, Azzopardi et al. 2009). Recently in the UK, the National 
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Institute for Health and Clinical Excellence (NICE) recommended that therapeutic 
hypothermia for Hypoxic Perinatal Brain Injury should be offered to ‘carefully selected 
infants’ (NICE 2010).  
There are many neuroprotective actions of hypothermia after HI. Cerebral 
metabolism is approximately reduced 7% for every 1oC drop in core temperature, 
with consequently lower glucose and lower oxygen demand (Erecinska, Thoresen et 
al. 2003). Hypothermia reduces free radical production and glutamate levels, thereby 
preserves mitochondrial function (Gunn and Gunn 1998). It also decreases apoptosis 
by inhibiting caspase 3 activation and decreasing Bcl-2 expression (Edwards, Yue et 
al. 1995).  
The safety aspect of therapeutic hypothermia is well established from all clinical 
trials. Thrombocytopenia and arrhythmias are frequently associated with therapeutic 
hypothermia (Shah 2010), but these can be corrected in the setting of an 
experienced neonatal intensive care unit. Use of ionotropes was also observed in 
some studies with hypothermia; however, they are due to physician bias rather than 
actual need (Battin, Thoresen et al. 2009). In addition, there is a need to re-warm as 
slowly as possible – by a maximum of 0.5oC over 2 hours, because adverse effects 
can occur during rewarming (Battin, Bennet et al. 2004). Furthermore, it is very 
important to avoid over-cooling below the recommended temperature, which has 
been associated with adverse outcomes (Rohrer and Natale 1992, Sessler 2001, 
Polderman 2004) 
Adjunct therapies 
Approximately half the infants with HIE, who receive therapeutic hypothermia, still 
have an abnormal outcome(Edwards, Brocklehurst et al. 2010). Evidence from 
animal studies suggests that hypothermia extends the duration of the therapeutic 
window and certain drugs given during this time may augment neuroprotection (Liu, 
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Barks et al. 2004). Research is now being focused on pre-clinical studies of drugs, 
which act synergistically or additively with hypothermia.  Promising agents include 
erythropoietin, N acetyl cysteine (NAC), melatonin, 2-immunobiotin and inhaled 
xenon (Kelen and Robertson 2010). 
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1.7 Cerebral Magnetic Resonance Spectroscopy 
Biomarkers 
Introduction 
A National Institutes of Health working group defined biomarker as a characteristic 
that is objectively measured and evaluated as an indicator of normal biologic 
processes, pathogenic processes, or pharmacologic responses to a therapeutic 
intervention(Atkinson AJ 2001). Bridging biomarkers are the ones that detect an 
effect in both animals and humans and they allow the transfer of information from 
experimental to human studies. As research is now being focused on preclinical and 
clinical studies of neuroprotective drugs, which acts synergistically with therapeutic 
hypothermia, early biomarkers are urgently needed to select the infants, at risk of an 
abnormal outcome, for neuroprotective intervention. Late biomarkers are also 
needed to prognosticate long term neurodevelopmental outcome following these 
neuroprotective interventions to avoid the delay between intervention and long-term 
outcome. Magnetic resonance spectroscopy (MRS) can provide valuable information 
on cerebral energy metabolism following hypoxia-ischemia that can be used as early 
or late biomarkers.  
Proton magnetic resonance spectroscopy (1HMRS) Biomarkers 
Several MRS studies have used 1H MRS because the greater sensitivity of the 1H 
nucleus allows more accurate regional measurements. Within the 1H spectrum, 
peaks can be assigned using appropriate scanning parameters to N-acetyl aspartate 
(NAA), choline-containing compounds (Cho), creatine plus phosphocreatinine (Cr), 
lactate (Lac), myoinositol (mI) and alanine, glutamine and glutamate (Glx).  In 1H 
MRS, the NAA resonance is a singlet and can be observed easily as a peak with a 
chemical shift of 2.02 ppm over a wide echo-time (TE) range (Figure1.12). However, 
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the cerebral Lac resonance visualized easiest is the methyl doublet with J coupling of 
~6.93 Hz(Kingsley 1994): as a result the Lac doublet undergoes phase modulation 
and point-resolved spectroscopy (PRESS; an often-used single-voxel localization 
technique) detection is optimized for TE 144 ms (inverted signal) and TE 288 ms 
(upright signal)(Ernst and Hennig 1991). The Lac doublet is observed at 1.33ppm 
(Figure 1.12). 
Cerebral Lac rises during hypoxia-ischemia and normalises soon after resuscitation 
and reperfusion(Lei and Peeling 1998). There is a secondary, delayed rise in Lac 
several hours after hypoxia-ischemia due to renewed production or impaired 
mitochondrial utilization (Penrice, Lorek et al. 1997). This secondary Lac rise can 
persist for a long time (Hanrahan, Cox et al. 1998) and is associated with brain 
alkalosis (Robertson, Cowan et al. 2002). The presence of Lac is thought to reflect 
neural injury as well as the inflammatory reaction to damage through microglia 
activation(Garcia and Kamijyo 1974). NAA is unique not only by virtue of its 
exceptionally high concentration in the brain, but also due to the powerful signal that 
it gives off in water-suppressed proton MRS spectrograms(Luyten and den Hollander 
1986). Evidence from several animal studies shows that decrease in NAA occur 
more slowly than Lac increases after focal ischemia(Barker P 2005). The lowest 
levels of NAA in animal studies are observed 50–70 hours after hypoxia-
ischemia(Higuchi, Fernandez et al. 1996). Large declines in NAA levels following 
hypoxia-ischemia parallel the onset of reduced neuronal numbers, reduced cell size, 
nuclear pyknosis and infiltration first of polymorphonuclear cells and mononuclear 
cells, which are most evident between 24 and 48 hours in focal lesions in rats (Lee, 
Burdett et al. 1996). A rise in myo-inositol (marker for glia) and glutamate may also 
be observed following hypoxia-ischemia with scanning parameters optimised to 
demonstrate these peaks(Groenendaal, Roelants-Van Rijn et al. 2001, Robertson, 
Lewis et al. 2001).  
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Over the last two decades, several clinical studies used these markers to predict 
neurodevelopmental outcome. Although absolute concentrations can be obtained, 
most studies measured metabolite ratios including Lac/NAA, Lac/Cr, NAA/Cho, 
NAA/Cr and Lac/Cho from peak areas. These studies have shown a significant 
association between a number of metabolite ratios and neurological outcome 
following asphyxia.A recent meta-analysis, which included all these studies, 
suggested that deep gray matter Lac/NAA, acquired between 5-14 days after birth, 
was the most accurate predictor of long term adverse neurodevelopmental outcome 
with a sensitivity of 0.82 (95% CI:0.74-0.89) and specificity 0.95 (0.88-0.99) (area 
under curve (AUC) 0.94 [SE 0.03])(Thayyil, Chandrasekaran et al. 2010). The 
median cut-off values of all the biomarkers are in table 1.4. 
 
Table 1.4: The median cut-off values of all 1H MRS biomarkers(Thayyil, 
Chandrasekaran et al. 2010) Permission to reproduce this table has been granted by American 
Academy of Pediatrics.  
Phosphorus magnetic resonance spectroscopy (31P MRS) biomarkers 
Phosphorus (31P) MRS defined the biphasic pattern of cerebral energy metabolism in 
infants with HIE, which is impairment of cerebral energy metabolism following several 
hours after birth despite adequate resuscitation in moderate to severe 
encephalopathic infants (Hope, Costello et al. 1984, Azzopardi, Wyatt et al. 1989). 
During transient hypoxia-ischemia in experimental models, similar biphasic cerebral 
energy metabolism impairments have been seen with decrease in PCr, NTP, and 
intracellular pH , and increase in Pi, but these rapidly return towards basal values on 
resuscitation followed by a "latent period" of apparently almost normal energetics 
(Lorek, Takei et al. 1994, Vannucci, Towfighi et al. 2004). Then, 12 to 24 hours later, 
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a fall in PCr and NTP, and increase in Pi was observed but these changes are 
unaccompanied by profound intracellular acidosis.  
Clinical studies using 31P MRS demonstrated a close relationship between severity of 
impairment in cerebral energy metabolism and adverse neurodevelopmental 
outcome (Azzopardi, Wyatt et al. 1989, Roth, Edwards et al. 1992). Following 
hypoxia-ischemia reduced cerebral PCr/Pi and NTP/total mobile phosphate (Ptot) 
ratios, and low PCr, NTP, and Ptot concentrations have been associated with 
eventual neurodevelopmental impairment and increased infant mortality (Azzopardi, 
Wyatt et al. 1989, Martin, Buchli et al. 1996). In particular, reduced NTP/Ptot was 
invariably associated with fatal outcome. Thus in clinical studies, PCr/Pi and 
NTP/Ptot, and PCr, NTP, and Ptot concentrations have proven useful biomarkers.  
Conclusion 
In summary, the cerebral 1H MRS Lac/NAA peak area ratio is the most accurate 
quantitative MR biomarker for prediction of neurodevelopmental outcome. However, 
31P and 1H MRS have not yet been shown to be effective biomarkers of treatment 
effect in human infants.  Further validation of all MRS biomarkers will be important for 
monitoring neuroprotective therapies and providing surrogate endpoints for future 
Phase II clinical trials of combinations of adjuvant drugs and therapeutic 
hypothermia. 
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1.8 Aim and Hypotheses 
To explore the precise role of MRS as a biomarker in perinatal hypoxia-ischemia, 
further studies are needed to assess the relation between MRS and outcome 
measures such as neuronal cell death and/or neurodevelopmental outcome. It is also 
essential to determine the effect of neuroprotective treatments on MRS and whether 
similar relationships between MRS and outcome measures exist. We have used the 
piglet model to test the following hypotheses.  
Hypothesis 1: Early 1H MRS and 31P MRS biomarkers (EBMs), acquired within first 4 
hours after global hypoxia-ischemia, correlate with neuronal injury assessed at 48 
hours after hypoxia-ischemia in the piglet asphyxia model.  
Currently, therapeutic hypothermia should be started for infants with NE as soon as 
possible after diagnosis, usually within 6 hours of birth (NICE 2010). Hence there is a 
short period (termed as therapeutic window) available for diagnosis before starting 
any neuroprotective treatment. During this therapeutic window, infants are selected 
to receive therapeutic hypothermia on the basis of history of events related to birth, 
abnormal clinical examination, presence of seizures and abnormal amplitude 
integrated EEG. However, there is no perfect tool available early to detect possible 
short-term outcome or ideal candidate for neuroprotective intervention. During this 
therapeutic window, MRS could be performed, once the infant is stabilized, to predict 
the outcome of the baby before starting neuroprotection. Hence we formulated this 
hypothesis to identify whether early MRS biomarkers can predict neuronal injury 
assessed at 48 hours by MRS and histology.  
 
Hypothesis 2: Late 1H MRS and 31P MRS biomarkers, acquired at 48 hours of 
hypoxia-ischemia, correlate with neuronal cell death assessed at 48 hours after 
hypoxia-ischemia in the piglet asphyxia model; this holds true with and without 
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neuroprotective intervention. The two neuroprotective interventions we describe are 
Xenon/hypothermia (Faulkner, Bainbridge et al. 2011) and N-Methyl-Isobutyl-
Amiloride (MIA) (Robertson, Kato et al. 2013).  
Over the last two decades, several clinical studies used 31P and 1H MRS to predict 
neurodevelopmental outcome in infants with NE. These clinical studies demonstrated 
a close relationship between metabolite ratios (1H MRS) /severity of impairment in 
cerebral energy metabolism (31P MRS) and adverse neurodevelopmental outcome. 
However, 31P and 1H MRS have not yet been shown to be effective biomarkers of 
treatment effect in human infants.  Further validation of all MRS biomarkers will be 
important for providing surrogate endpoints for future clinical trials of combinations of 
adjuvant drugs and therapeutic hypothermia. Hence we formulated this hypothesis to 
assess the predictive ability of MRS biomarkers after neuroprotective intervention.  
Hypothesis 3: We have extended hypothesis 2 in a clinical cohort of infants at UCH. 
In a clinical cohort of infants with neonatal encephalopathy (NE), half of whom 
received hypothermic neuroprotection, 1H MRS biomarkers, acquired between 5 and 
14 days after birth, predict neurodevelopmental outcome at 18 months age. 
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Chapter 2 - Materials and Methods
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Animals 
Large white male piglets (1.6 – 2.0 Kg) aged < 24hrs were used for all experiments. 
Experiments were performed under UK Home Office Guidelines (Animals Scientific 
Procedures Act 1986) and with the project licence (PPL 70/6355). 
Initial preparation 
On the morning of the experiment, the piglet was sedated on arrival with 
intramuscular midazolam (0.2mg/kg) and moved to a resuscitaire (Figure 2.1) for 
surgical procedures. Isoflurane anesthesia (initial concentration 4% (v/v)) was given 
through a facemask to induce anaesthesia. The piglet was laid supine with its head 
immobilised and all limbs loosely restrained with string. Isoflurane anaesthesia was 
then reduced to 3% for surgery. Arterial oxygen saturations and heart rate were 
monitored with pulse oximeter (NoninMedical,USA) and O2 saturations maintained 
above 92%. The rectal temperature was maintained at normothermia (38.5 oC +/- 0.5 
oC) with the help of an overhead heater.  
Tracheostomy  
The skin site was cleaned with povidine iodine and an incision was made with a 
sterile scalpel blade between top of rib cage and the area just below the laryngeal 
prominence. Using blunt forceps, the skin, muscle and connective tissue were gently 
resected in a vertical direction. The trachea was located and isolated from 
surrounding connective tissue and two lengths (10cm) of Mersilk suture were pulled 
through underneath the trachea. These suture threads were separated and 
positioned at either end of the isolated trachea. The trachea was cut to 50% of its 
depth (180o cut) between the cartilage rings. The endotracheal (ET) tube (3.5-4mm 
inner diameter) was inserted swiftly into the tracheal opening and the depth of the 
tube maintained around 2.5cm. The ventilator circuit was attached to the ET tube and 
continuous mandatory ventilation (CMV) mode of ventilation with a peak inspiratory 
pressure (PIP) of 15cmH20, positive end expiratory pressure (PEEP) of 4cmH20 and 
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rate of 12/min. The ET tube was secured anterior and posterior of the incision point 
with the sutures. The ventilator settings were adjusted to maintain partial pressure of 
oxygen (PaO2) and carbon dioxide (PaCO2) at 8-13 kPa and 4.5-6.5 kPa, 
respectively.  
 
Figure2.1: Resuscitaire and pod 
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Carotid artery occluder placement 
Once the tracheostomy was completed and the animal stable on mechanical 
ventilation, the carotid artery was located on one side of trachea and gently dissected 
with forceps from the surrounding tissue and nerve at the level fourth cervical 
vertebra. Landmarks for the artery were medial to the trachea with the vein lateral 
and the nerve beneath. Once isolated, the artery was elevated with forceps a 
vascular occlude (OC2A, In Vivo Metric, Healdsburg, California, USA.) was placed 
around the artery ensuring cuff size and artery diameter were matched closely. A 
suture was passed through the fixation holes in the cuff and the artery was released 
within 1 minute to lie in its original position. The first knot was tied firmly and the 
second knot loosely to hold the occlude in position. The cuff was manually inflated to 
check for successful inflation, to ensure complete vessel occlusion, and to ensure the 
return of normal pulsations when the artery was released. Following this the second 
knot was fixed tightly and the double knot repeated. The artery was relocated to its 
original position within the surrounding tissue, ensuring that the artery direction was 
vertical and the cuff lay perpendicular to this. The same procedure was repeated on 
the other carotid artery. The skin was closed using Mersilk sutures and ‘return suture’ 
technique ensuring no restriction of the occluder-tubing occurred. 
Umbilical vessel catheterisation 
For the umbilical arterial catheterisation, a single lumen catheter (3.5Fr) was 
attached to a 3-way tap followed by an extension tube. For venous catheterisation, a 
double lumen catheter (3.5Fr) was used with a 3-way tap on each end. The skin site 
was cleaned with povidine iodine. The umbilical cord was removed with a sterile 
scalpel at the boundary of live/dead tissue. Umbilical vessels were identified (2 
arteries-smaller and thin walled; 1 vein- larger, thick walled) and isolated. The artery 
was dilated with the inset tip of thin tip forceps, 3-5 mm down the vessel. Holding the 
edge of the vessel with forceps, a single lumen catheter was inserted into the artery 
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until a depth of approx. 7-9cmwas achieved. Once blood flow was observed, the 
catheter was secured by suturing the surrounding skin and to the catheter with 3 x 
knotted sutures. The same procedure was repeated for catheterising the umbilical 
vein, leaving the catheter 5cm from the skin surface. The catheter lines were taped 
together then both catheters were taped in a loop to the lower abdominal region. 
When difficulties with umbilical vessel catheterisation were encountered, the femoral 
artery and vein were catheterized instead using 22-20G intravenous catheters. 
Locating animal into pod 
After surgery, the piglets were positioned prone in a plastic pod.  A bite bar was 
located in the mouth and hooked onto the upper canines. It was secured with tape 
and fixed firmly with a cable tie. The animal was placed prone, the head was secured 
into a stereotactic frame and ear bars were firmly positioned against the temple 
(Figure 2.2). All tubes, catheters and cables were carefully arranged. The animal 
remained in the pod until the end of the experiment. 
Monitoring  
All animals received continuous physiological monitoring and intensive life support 
throughout the experiment. Continuous heart rate, ECG, arterial oxygen saturations, 
arterial blood pressure, rectal temperature was recorded continuously (SA 
instruments, NY, USA) (Figure 2.3). Intermittent blood sampling was performed from 
the umbilical arterial line and PaO2, PaCO2, pH, electrolytes, glucose, and lactate 
(Abbot Laboratories, UK) were measured 6hrsly and temperature corrected (Abbott 
istat, UK). Trace EEG and aEEG were monitored continuously whenever the animal 
was outside the 4.7 T magnet bore with a Brainz CFM monitor. 
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Figure2.2: Animal in the pod, ventilated via tracheostomy and needle electrodes for 
EEG 
 
Figure 2.3: Vital signs including HR, BP, Oxygen saturations and temperature 
monitoring during the experiment
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Fluids and Drugs 
Maintenance fluids (10% dextrose, 60ml/kg/day) were infused through the umbilical 
venous catheter throughout the experiment. Antibiotics (Benzyl penicillin 50mg/kg 
and gentamicin 2.5mg/kg, every 12 h) were administered intravenously. Arterial lines 
were maintained by infusing 0.9% saline solution (Baxter, 1ml/h): heparin sodium 
was added at a concentration of 1 IU/ml to prevent line blockage. Bolus infusions of 
colloid (Gelofusin, B Braun Medical Ltd. Emmenbrucke, Switzerland) and ionotropes 
including dopamine(5-20µg/kg/min) dobutamine(5-20µg/kg/min) and adrenaline (0.1 
– 120µg/kg/min)  maintained mean arterial blood pressure (MABP) >40mmHg. 
Seizures, whenever observed, were treated with phenobarbitone (20mg/kg repeated 
if necessary). 
Pain control 
Isoflurane anesthesia (initial concentration 4% (v/v)) was administered during 
surgery. The Isoflurane concentration was reduced following the initial surgical 
procedures and thereafter kept at around 2%. A continuous fentanyl infusion (3 – 
6µg/kg/hour) was given through the umbilical venous catheter. Adequate sedation 
and analgesia were maintained throughout the experiment.  
Termination and Perfusion  
Forty-eight hours after the hypoxic-ischemic insult, the animal was euthanized with 
pentobarbital (6ml) followed by saline (5ml) bolus, both given through the umbilical 
venous line. The animal was laid supine in a tray so its head was in line with its body. 
Carotid artery occluders were first removed; an incision was made along the midline 
of the chest with a scalpel starting from manubrium sterni and then laterally following 
the underside of the rib cage to form an inverted ‘Y’. The skin overlying the rib cage 
was separated with the blunt end of forceps. Using large blunt scissors, the thoracic 
cavity was punctured at the base of the rib cage and cut medial to lateral and 
anterior, towards the shoulder through the rib cage on each side. Parting the 
75 
 
connective tissue exposed the heart. The rib cage was cut open at the sternum and 
folded back towards head holding it in place with a heavy pair of surgical clamps. 
Once the heart was fully exposed, a small incision was made in the left ventricle and 
a small catheter was passed through the incised hole the point of the catheter 
reached the aortic arch. Then PBS was slowly infused (approximately 50mls over 
1min) through the catheter with a syringe, ensuring that there were no air bubbles in 
the syringe. A small incision was made in the right atrium additionally to ensure blood 
was able to drain out during perfusion. Once 400mls of PBS had been infused, a 
similar volume of PFA was infused through the same catheter.   
Removal of brain 
Once the perfusion process was completed, the animal was turned over to expose 
the skull and the skull cleaned. A skin incision was made from the snout to the back 
of skull and down the neck and spine until mid thorax. Then skin was separated from 
skull bone, cutting away connective tissue and muscle surrounding the neck and 
spine. C1 was located and with sharp bone cutters, the bone was cut down either 
side of the atlas to release the spine. Using fine scissors, the dura matter over spinal 
column was removed. Starting from the base of the skull, the skull bone was cut in 
small pieces using bone cutters pulling excised skull away parallel to the surface of 
the brain. Exposing the cerebellum and working forward, bone was cut and removed 
over the whole cortex down to the level of the optic socket ensuring no sharp edges 
were protruding. The dura matter was removed from the surface of brain using fine 
forceps and fine scissors. Following this the brain, including the cerebellum, was 
carefully removed from the skull, cutting the olfactory and optic nerves proximally and 
cutting through any remaining brain stem distally (Figure 2.4 and 2.5).  
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 Figure 2.4: Whole brain after post-mortem examination 
 
 Figure 2.5: Sagittal view of left sided brain 
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Tissue preparation 
The brain, once removed from the skull, was immediately placed in 2% PFA. It was 
stored at 4˚Cfor 7 days before processing. Once the brain was fixed, coronal slices 
(5mm thick) of the right hemisphere, starting from anterior to the optic chiasma, were 
cut processed and embedded in paraffin wax. Brain tissue was mounted frozen on 
dry ice, and stored at -80˚C until required. The brains were cut on a cryostat and 
were then sectioned to 5µm thickness onto a slide for subsequent 
immunohistochemistry staining.  
Histology  
Qualitative analysis of tissue integrity and neuronal damage was examined in both 
hemispheres using haematoxylin and eosin (H&E) stain. To assess cell death and 
glial activation, adjacent sections were stained for nuclear DNA fragmentation using 
histochemistry with transferase mediated biotinylated d-UTP nick end-labeling 
(TUNEL),and the appearance of cleaved caspase 3 and microglial ionized calcium-
binding adaptor molecule 1 (IBA1) immunoreactivity. For all 3 stains, brain sections 
were dehydrated in xylene (3x10 min) and rehydrated in graded ethanol solutions 
(100-70%), followed by double-distilled water.  
TUNEL staining 
For TUNEL, the sections were pretreated for 15 min in 3% H2O2 in methanol to 
remove endogenous peroxidase, followed by a 15 min peptidase pre digestion with 
20 ug/ml Proteinase K (Promega, UK) at 65oC, and then incubated at 37oC for 
2hours with the TUNEL solution (Roche, UK) containing biotinylated dUTP. The 
reaction was stopped by incubating the slides for 10 minutes in 300 mM sodium 
chloride / 300 mM sodium citrate (TUNEL stop solution). The biotin residues were 
detected with the avidin-biotinylated horseradish peroxidase complex(ABC, Vector 
Laboratories, Peterborough, UK) and visualized with diaminobenzidine/H2O2 (Sigma, 
UK), with CoCl2 and NiCl2 included to intensify TUNEL histochemistry. The reaction 
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was stopped in 10mM PB and the sections washed twice in double-distilled water. The 
sections were dehydrated in70%, 90%, 95% and 100% ethanol, isopropanol, and 
twice in xylene, 2 minutes in each before being covered using Depex. 
Caspase staining 
For Caspase staining, the sections were pretreated for 15 min in 3% H2O2 in 
methanol to remove endogenous peroxidase activity and processed for antigen 
retrieval (800 mW microwave irradiation in 0.1M citrate buffer, 10min), followed by 
overnight incubation with primary rabbit antibody against caspase 3 (1:500). The 
biotin residues were detected with the avidin-biotinylated horseradish peroxidase 
complex (ABC, Vector Laboratories, Peterborough, UK) and visualized with 
diaminobenzidine/H2O2 (Sigma, UK). The sections were counterstained with 
haemotoxylin, dehydrated in graded alcohol and xylene, and mounted with Depex 
(VWR, UK). 
Iba1 staining 
The Iba1 antibody was diluted 1:1000 in Bond Primary Antibody Diluent. The 
sections were then processed on the Bond Max Automated IHC Stainer, using a pre-
programmed staining schedule that dewaxed the slides (using Bond Dewax solution), 
then pre-treated the sections with Bond Epitope Retrieval solution 2 (an EDTA buffer 
with surfactant at pH8.8) for 30 minutes. The staining protocol itself used Bond 
Polymer Refine reagents to block peroxidase/catalase reactivity using 3% Hydrogen 
Peroxide for 5 minutes, the diluted primary antibody (Ib1a) was then incubated for 15 
minutes, followed by a "Post-Primary" incubation, described as a 'polymer 
penetration enhancer' for 8 minutes, then the Polymer, which was the final layer, for 8 
minutes, then with DAB for ten minutes. Bond DAB Enhancer (0.5% Copper sulphate 
in saline, with surfactant) was then applied for 5 minutes, followed by a Haematoxylin 
counterstain for 5 minutes. Each step was separated by three brief washes in 
Bondwash solution (a Tris buffered saline solution, diluted x10 with deionised water 
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for working solution). The stained sections were then removed and taken to an 
automated staining machine (Leica ST5020)/cover slipper (Leica CV5030), where the 
sections were dehydrated through graded alcohols (BDH), cleared in AnalaR xylene 
(BDH), and mounted with coverslips (BDH) using Pertex Mounting Medium from Cell 
Path. 
Quantification of stained cells 
For each animal, quantification was performed in the dorsal cortex (3 regions), mid 
temporal cortex (insular region), caudate nucleus, thalamus, putamen, peri-
ventricular white matter and hippocampus (dentate gyrus). All the counted regions 
are shown in figure 2.6. The 3 fields were from the superficial, middle and deep 
cortical layers for cortex and random 3 fields for other regions. TUNEL+ nuclei were 
counted in 3 fields per region (at 40x magnification, with an area of 0.76mm2) and the 
average converted into counts per mm2. The less numerous caspase 
immunoreactive cells were counted at 20x magnification (3 fields, 3.1mm2).  
IBA1+ microglial cell bodies and branch density were determined at 40x 
magnification using a 0.24x0.24mm square grid, placed in 3 fields for each brain 
region and counting the number of cell bodies inside the grid (CBD) and the average 
number of branches (B) crossing the 3 horizontal (top, middle and bottom) and the 3 
vertical (left, middle and right) 0.24mm long gridlines. This determined the microglial 
ramification index (B2 / CBD). 
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Figure 2.6: Representative piglet brain photomicrograph indicating brain regions 
assessed for histology and immunohistochemistry. Permission to reproduce this figure has 
been granted by Oxford University Press. 
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Magnetic Resonance Spectroscopy (MRS) 
MR spectra were acquired using a 6.5 cm x 5.5 cm elliptical transmit-receive surface-
coil tunable for both proton (1H) and phosphorous (31P) nuclei on a 4.7 Tesla Biospec 
Avance (Bruker Medizintechnik, Karlsruhe, Germany) (Figure 2.6). Baseline spectra 
were acquired prior to hypoxia-ischemia, during hypoxia-ischemia and recovery (31P 
only), and thereafter continuously with cycle time ~5 h. PRESS 1H MR spectra were 
acquired from 2 positions: ventromedial forebrain centred on both lateral thalami and 
hypothalami (ventromedial-forebrain; 14mm x 14mm x 7mm voxel); and dorsal right 
sub-cortical white matter at the centrum semiovale level (WM; 9mm x 4mm x 20mm 
voxel). 1H spectra were acquired with repetition time (TR) 5 sec, 128 summed 
transients, and echo times (TE) 25 ms, 144 ms, and 288 ms.31P MR spectra were 
acquired from whole brain using single-pulse acquire with TR 10 s. 
 
MRS Analysis 
1H spectra were analysed using LCModel. For each spectrum the relative signal 
amplitudes of choline (Cho), total creatine (Cr), N-acetyl-aspartate (NAA) and lactate 
(Lac) were measured. For statistical analysis, the primary 1H MRS outcome measure 
nominated a priori was Lac/NAA. Metabolite peak-area ratios were plotted from 
baseline to 48 h after hypoxia-ischemia for each voxel in each subject and analysed 
according to the randomized group. 
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 Figure 2.7: 4.7 Tesla Bruker MR system in the designated magnet room 
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31P MR spectra were analysed by AMARES. Signal amplitudes and chemical shifts 
were measured for phosphocreatine (PCr), Pi (3 independent components fitted) and 
α-, β-, and γ-NTP; the equivalent signal amplitude for EPP was also calculated. 
Intracellular pH (pHi) was measured from the difference between the PCr and 
amplitude-weighted mean Pi chemical shifts. Metabolite peak-area ratios were 
plotted from baseline to 48 h after hypoxia-ischemia for each experimental group. 
Cerebral hypoxia-ischemia 
Whilst in the MRS system, transient hypoxia-ischemia was induced by remote 
occlusion of both the common carotid arteries, using the inflatable vascular 
occluders, and reducing fractional inspired (Fi) O2 to 12 % (v/v).  During transient 
hypoxia-ischemia cerebral-energetic changes were observed every 2 min by 
phosphorus (31P) MRS and the β-nucleotide triphosphate (NTP; mainly ATP) peak 
height was automatically generated.  Hypoxia-ischemia was continued until 10 min 
after the β-NTP peak height had fallen to 40% of baseline for Xenon experiment and 
30% of baseline for Amiloride experiment.  During this 10 min period, FiO2 was 
adjusted in order to keep β-NTP peak height as close to the expected of baseline as 
possible. At the end of this 10 min period, the occluders were deflated and FiO2 was 
normalised. 31P MR spectra were acquired for a further hour to monitor recovery from 
hypoxia-ischemia. The time integral of the change in β-NTP peak area relative to the 
exchangeable phosphate pool (EPP = inorganic phosphate (Pi) + phosphocreatine 
(PCr) + (2γ+β)-NTP) during hypoxia-ischemia and the first 60 min of resuscitation 
gave the magnitude of acute energy depletion (AED). 
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 Figure 2.8: Quantification of insult severity. Global hypoxic and cerebral ischemic 
insult by occlusion of both carotid arteries and reduction of oxygen until β-NTP 40% 
baseline, held for 10 minutes in Xenon study 
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Experimental groups 
In this thesis, I am discussing the data of two of our experimental series investigating 
neuroprotective therapies. My primary involvement in these studies includes all 
histological methods (staining and quantification) and correlating MRS biomarkers 
with these histological markers using appropriate statistical methods. I also 
contributed towards data collection and the studies for both the experiments. A team 
of physicists and scientists helped with the experiments. However, I have worked 
along them in this model using the Bruker 4.7T system (approximately 30 
experiments) as well as in a further two experimental series on the Varian 9.4T MR 
system. These studies have given me insight and knowledge about the animal model 
and the science behind the animal research. All the data analysed and discussed in 
the following chapters are from the first 2 neuroprotection experiments on the Bruker 
MR system.  
1. Xenon/ Hypothermia experiment  
Baseline data were acquired before transient hypoxia-ischemia but after 
stabilization of the animal in the MRS system. Following transient hypoxia-
ischemia, 36 piglets were randomised into 4 groups (each n=9), with 
intervention from 2-26 h: Group (i) normothermia (38.5oC); Group (ii) 
normothermia + 24 h 50% inhaled xenon; Group (iii) 24 h therapeutic 
hypothermia (rectal temperature (Trectal) 33.5oC) or Group (iv) 24 h 50% 
inhaled xenon +24 h therapeutic hypothermia (Trectal 33.5oC). Normothermic 
piglets were maintained at their target Trectal using a warmed water mattress 
under the piglet and circulating warm air; hypothermic piglets (Groups (iii) and 
(iv)) were cooled (by water mattress) over 90-120 min to a target Trectal of 
33.5oC, which was maintained between 2-26 h following hypoxia-ischemia. At 
26 h after hypoxia-ischemia piglets were re-warmed to normothermia at 
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0.5oC/h (Faulkner, Bainbridge et al. 2011).  
2. Methyl Isobutyl Amiloride (MIA) experiment 
Baseline data were acquired before transient hypoxia-ischemia but after 
stabilization of the animal in the MRS system. Following transient hypoxia-
ischemia, 18 male piglets (<24 h of age) were randomized to 2 groups (each 
n=9) (1) normothermia; or (2) 2.5mg/kg of MIA at 10 mins after resuscitation 
and 8 hourly thereafter (Robertson, Kato et al. 2013). 
Statistics 
All metabolite ratios were converted to a logarithmic (log) scale before analysis. The 
integrating, 48h Area Under the Curve (AUC) data for the metabolite ratios were 
calculated from the log values. Where metabolite ratios decreased during the 48h 
after HI (PCr/ePP, NTP/ePP, NAA/Cr), the ratio-specific integral value was 
determined using Area Over the Curve (AOC); AOC was also used for Acute Energy 
Deficit (AED) and for assessing pH changes. Area under the curve (AUC) was used 
as a generic term for the whole set of MRS outcome measures. When a specific 
metabolite is mentioned, it is AUC in case of metabolite ratios increasing after HI 
(Lac/Cr, Lac/NAA, Pi/ePP), and AOC in case of decreasing ones. All statistics for 
histopathology outcomes were performed on data transformed by the f=log(x+a) 
algorithm with a=1 for TUNEL and caspase 3+ density, and a=0.1 for microglial 
ramification. All other ratios (metabolite ratios, actual/expected ratios) were analysed 
using simple log values.  
Predictive Analytics Software 18 (PASW; IBM, USA) was used for all statistical for 
late biomarkers analysis.  Multiple linear regression analysis was done to assess the 
relationship of early and late biomarkers with the outcome. Statistical significance of 
the R2 value was assessed using the F-test. The differences between the groups 
detected using one-way ANOVA, followed by post-hoc Tukey test. Paired and 
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unpaired t test was used when appropriate. Correlation plot R2 values were tested for 
significance using F-test.  
88 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
89 
 
 
 
 
 
 
 
Chapter 3 - The Predictive value of Early 
MRS Biomarkers (acquired within 4 hours 
after HI) without neuroprotective 
intervention in a piglet model of HIE
90 
 
Introduction 
 
The course of the encephalopathy following hypoxia-ischemic (HI) episodes is very 
variable and it is difficult to predict the outcome of an individual patient early and 
particularly early after reperfusion. A better prediction of the outcome at early time 
points would greatly facilitate future neuroprotection trials and clinical decisions. In 
order to accelerate translation of research to clinical practice, biomarkers are needed 
to better quantify the severity of the hypoxic-ischemic brain injury. This will help us to 
select the right candidate, who would develop moderate or severe encephalopathy, 
for future neuroprotection trials. 
 
We defined MRS data (proton and phosphorus) that were acquired at first time point 
after the HI as early biomarkers (EBM). Our aim was to investigate early MRS 
biomarkers (EBM), acquired between 2 and 4 h after HI, and their correlation to MRS 
and histological outcome in a piglet model of HIE. 
Materials and methods 
 
Experiments were carried out according to United Kingdom Home Office guidelines. 
Large-white male piglets, aged < 24h were anesthetised and surgically prepared as 
described previously (Lorek, Takei et al. 1994, Faulkner, Bainbridge et al. 2011). All 
physiological monitoring and procedures during experiment were done as explained 
previously(Faulkner, Bainbridge et al. 2011). All data used in the current study were 
from two large translational neuroprotection studies in a piglet model of hypoxic-
ischemia. The first study (Faulkner, Bainbridge et al. 2011) explored the combination 
of hypothermia and Xenon (Xe/HT), the second (Robertson, Kato et al. 2013) the 
treatment with Methyl-Isobutyl-Amiloride (MIA). MRS acquisition (Figure 3.1) and 
analysis, statistics, histological staining and quantification and hypoxia-ischemia were 
as described in previous chapter.  
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Figure 3.1: Voxel position, typical proton and phosphorus spectra; baseline and 4 
hours after HI in untreated animals. 
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Physiological Measures  
There were no intergroup differences in body weight, postnatal age, baseline 
physiological (HR and MABP) and biochemical measures (blood lactate, base excess 
and glucose) (Appendix Tables 1 and 2). Insult severity qualified with triphosphate 
levels and PaO2 and PaCO2 were similar between groups during HI and time to 
reach target rectal temperature during post HI hypothermic induction was similar.  
During cooling induction (2-3.5h), maintenance (3.5-26h) and re-
warming/normothermia (26-48h) periods, mean HR and MABP and blood chemistry 
and electrolytes (pH, lactate, base excess, glucose) were similar between groups 
(Appendix Tables 1 and 2). In the MIA study, two piglets from the saline placebo 
group died at 24 and 32 h; 1 MIA piglet died at 30h because of complications 
secondary to severe HI. All other subjects survived until the end of experiment, 48 
hours after the insult. In the Xe/HT study, four piglets were terminated prior to 48-
hour post insult due to ventilator problems in 2 cases and complications secondary to 
severe hypoxia–ischemia (1 case each from the xenon alone and hypothermia alone 
groups and 2 cases from the combined xenon and hypothermia group). 
Description of Early Biomarkers and Outcome data 
 
For early biomarkers, we used the single point MRS data from the first time point, 
which is acquired 2-4 h after completion of HI insults (Tables3.1 and 3.2). These data 
include 1H MRS WM and thalamic voxels (Lac/Cr, NAA/Cr and Lac/NAA), and the 31P 
MRS whole brain voxel (Pi/ePP, PCr/ePP, NTP/ePP and pH(Pi)). We also used 
Acute Energy Deficit (AED), which was calculated as described previously. All these 
11 markers are described as early biomarkers (EBMs). 
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Group 31P-Whole Brain  
time in hours 
mean+SEM (n) 
1H-WM voxel  
time in hours 
mean+SEM (n) 
1H-thalamic voxel 
time in hours 
mean+SEM (n) 
Control 2.04+0.02 (8) 3.95+0.09 (9) 2.97+0.04 (9) 
Xenon 2.02+0.01 (8) 4.39+0.17 (9) 3.40+0.17 (9) 
Hypothermia 2.11+0.05 (7) 4.43+0.17 (9) 3.34+0.12 (9) 
Combined 1.99+0.04 (8) 3.96+0.13 (8) 3.09+0.11 (9) 
 
Table 3.1: Early Marker Acquisition Time Point (hours) and Group Size for Xe/HT 
study 
 
Group 31P-Whole Brain  
 time in hours 
 mean+SEM (n) 
1H-WM voxel  
time in hours  
mean+SEM (n) 
1H-thalamic voxel 
time in hours 
mean+SEM (n) 
Saline 4.47+0.24 (9) 3.52+0.21 (9) 2.56+0.19 (9) 
MIA 5.11+0.39 (9) 3.80+0.16 (9) 2.71+0.13 (9) 
 
Table 3.2: Early Marker Acquisition Time Point (hours) and Group Size for MIA study 
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We compared EBMs with MRS area under the curve data (a value from all the MRS 
data points over 48h to give a value encompassing information about the trajectory of 
injury) and histological and immunohistochemistry data. MRS data included twelve 
outcomes (area under the curve); 4 from the 1H dorsoparietal subcortical white matter 
(WM) voxel (Lac/Cr, Cho/Cr, NAA/Cr and Lac/NAA), 4 from the 1H ventromedial 
forebrain (thalamic) voxel (Lac/Cr, Cho/Cr, NAA/Cr and Lac/NAA), and 4 from the 31P 
whole brain voxel (Pi/ePP, PCr/ePP, NTP/ePP and pH(Pi)). Neither the WM nor 
thalamic Cho/Cr AUC data showed insult-specific change in either of the two studies, 
and thus not included in further analysis. For histopathology outcomes, density of 
TUNEL+ nuclei, density of cleaved caspase 3 positive cells, and the ramification 
index were used. In further analysis, individual histopathology outcomes for each 
animal and staining were combined by using an average across all regions, with the 
intention to reduce the number of outcomes to 3 for each animal. Previous analysis 
revealed that these averaged histopathology values exhibited considerably higher 
correlation with the biomarker AUCs than those observed for region-specific 
histopathology (Faulkner et al, 2011). Overall, a total of 13 standardized outcomes, 
from MRS and histology, were used for analysis.  
Results 
 
In each animal, EBMs for 31P whole brain, 1H WM voxel, and 1H thalamic voxel were 
acquired consecutively: 31P MRS-derived EBMs were obtained between 1.7-2.3 
hours after HI insult, those for the 1H thalamic voxel at 2.8-4.1 hours, and for the 1H 
WM at 3.6-5.5 hours in Xe/HT study. The mean and standard error of the mean for 
the acquisition time point for Xe/HT and MIA studies, and the number of animals with 
this first data point inside the above time frames are shown in tables 3.1 and 3.2. 
There was no difference in the acquisition time point for all EBMs between the 
subgroups in both studies.  
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The values of all early biomarkers peak area ratios of all control animals are given in 
the table 3.3 and figure 3.2. The mean for all increasing biomarkers for Xe/HT study 
are generally lower than those in MIA study, appropriately indicating the different 
severity in both studies (table 3.3). There is no significant difference in the mean 
value of all EBMs among all the study groups in Xe/HT study (figure 3.2A). However, 
compared with the saline controls shown in figure 3.2B, the average “increasing” 
EBM values (Lac/Cr, Lac/NAA, Pi/ePP) for the MIA group were consistently lower, 
and “decreasing” EBMs (NAA/Cr, PCr/ePP, NTP/ePP) higher, reaching statistical 
significance in the case of thalamic Lac/Cr (p<0.05). This may be due to the 
treatment effect as MIA is administered 10 minutes after HI in the treatment group.  
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Early Biomarkers 
Xe/HT study 
Mean (SD) 
MIA study 
Mean (SD) 
Thalamic Lac/NAA 0.41 (0.11) 0.72 (0.48) 
Thalamic Lac/Cr 0.67 (0.14) 0.97 (0.40) 
Thalamic NAA/Cr 1.37 (0.04) 1.32 (0.13) 
WM Lac/NAA 0.46 (0.18) 0.72 (0.48) 
WM Lac/Cr 0.79 (0.19) 1.03 (0.40) 
WM NAA/Cr 1.44 (0.04) 1.38 (0.15) 
AED 0.10 (0.02) 0.13 (0.03) 
Pi/EPP 0.21 (0.04) 0.22 (0.05) 
PCr/EPP 0.28 (0.03) 0.27 (0.09) 
NTP/EPP 0.29 (0.04) 0.27 (0.08) 
pH (Pi) 7.17 (0.04) 7.07 (0.49) 
 
Table 3.3: MRS Early Biomarkers (EBMs) peak area ratios acquired between 2 and 
4 hours after HI for the Xe/HT and MIA study. Data shown as Mean and standard 
deviation  
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Figure 3.2: MRS Early Biomarker (EBMs) peak area ratios acquired between 2 and 
4 hours after HI for the Xe/HT (A) and MIA study (B).  All bars show mean+/- 
standard error of the mean (SEM), n = 9 animals per subgroup. The Y-axis is a 
logarithmic scale of the peak area ratio. The Xe/HT study consisted of 4 subgroups – 
control (ctrl), Xenon-treated (Xe), hypothermia (HT) and combined hypothermia and 
Xenon (Xe/HT). The MIA study consisted of only two groups – controls treated with 
saline and methyl-isobutyl amiloride (MI Amiloride). *p<0.05 in t-test for difference 
between saline and MIA-treated subgroups.   AED – Acute Energy Deficit, Cho – 
Choline to creatine ratio, L/N – Lactate to N-Acetyl Aspartate (NAA) ratio, Lac – 
Lactate to creatine ratio, NAA – NAA to creatinine, NTP – Nucleotide triphosphate to 
exchangeable phosphate pool, PCr – phosphocreatine to exchangeable phosphate 
pool, Pi – inorganic phosphorus to exchangeable phosphate pool, TH – thalamic, WB 
– Whole Brain, WM – dorsal subcortical White Matter. 
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Correlation of EBMs with MRS and Histopathology Outcomes in the 
Xe/HT study 
On regression analysis, thalamic Lac/NAA EBM showed positive and significant 
correlation with the thalamic Lac/NAA AUC outcome as shown in figure 3.3 (p<0.05) 
and table 3.4. On analysing with all remaining 12 outcomes for the untreated, control 
group, thalamic Lac/NAA showed a strong and significant correlation with R2 values 
(Figure 3.4). The only exception was the correlation with the log caspase 3 density 
(Figure 3.4F), where R2 value was low (0.11) and did not reach statistical significance 
(p=0.53). Of the 12 significant correlations, 11 displayed a positive regression slope 
and ramification index (Figure 3.4L) a negative slope.  
 
The results of regression analysis of all EBMs with outcome data are summarized in 
Table 3.4. On univariate regression analysis, as shown in table 3.4, the R2 values 
were particularly high for thalamic Lac/NAA EBM and moderate for thalamic Lac/Cr, 
WM Lac/Cr, and WM Lac/NAA. In the Xe/HT study, EBMs belonging to the 
“decreasing” group - WM and thalamic NAA/Cr, PCr/ePP, NTP/ePP – all displayed 
low R2 values. 
99 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4: Correlation between EBMs 
and the entire 12 outcome measures in 
Xe/HT study, The R2 and p values are 
obtained by univariate linear regression. 
EBMs, significant highly and with most 
outcome measures are bold. Thalamic 
Lac/Naa is highlighted with blue, as this 
was the only EBM, which significantly 
correlated with all the outcome 
measures 
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Figure 3.3: Thalamic Lac/NAA EBM (X-Axis) shows significant correlation with post-
HI thalamic Lac/NAA Area under the curve (AUC) (Y-Axis) in the control group of the 
Xe/HT study. The formulas represent regression line functions. 
Thalamic Lac/NAA EBM Thalamic Lac/NAA 
EBM 
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Figure 3.4: Correlation of thalamic Lac/NAA EBM (X-Axis) with in 9 additional MRS 
and 3 histopathology outcomes (Y-Axis) in the control subgroup of the Xe/HT study. 
Note the consistently high correlation R2 values (p<0.05) with MRS AUCs for WM 
Lac/NAA (A), Lac/Cr (B) and NAA/Cr (C), thalamic Lac/Cr (F) and NAA/Cr (G), whole 
brain Pi/ePP (E), PCr/EPP (I), NTP/ePP (J) and pH (K), as well as with 
histopathology values for log TUNEL density (D) an log microglial ramification (L). 
Correlation plot against log caspase 3 density (H) was the only exception, with an R2 
value of 0.106 (p=0.33). 
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Correlation of EBMs with MRS and Histopathology Outcomes in the MIA 
study 
 
To revalidate the predictive value of EBMs, the same analysis protocols were used 
for data from the MIA treatment study in a more severe form of HI insult. All 11 
markers (5 increasing EBMs, 4 decreasing EBMs, pH and AED) showed higher 
correlation for MRS and histopathology outcomes than those observed in the Xe/HT 
study (Table 3.5) with statistical significance (p<0.01). Correlation of thalamic 
Lac/NAA EBM was similarly high and significant with all MRS and histological 
outcome measures. All biomarkers, from both increasing and decreasing group, 
correlated with the outcome measure significantly (table 3.5) 
 
Correlation with Multivariable Regression 
As all the EBMs showed good correlation with the outcome measures by univariate 
regression model, we further analysed the data using multivariable regression model.  
We used Tunel density as the outcome measure for this analysis and all EBMS were 
entered as predictive variables. STEPWISE method of multivariable regression was 
used. Thalamic Lac/NAA showed high and significant correlation with Tunel density 
(p = <0.001) when compared to other EBMS, as shown in Table 3.6. This was true 
for both Xe/HT and MIA studies.  
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Table 3.5: Correlation    between 
EBMs and the entire 12 outcome      
measures in   MIA study, The R2 
and p values are obtained by  
univariate linear regression. 
Thalamic Lac/Naa is  highlighted 
with blue, as this was the only 
EBM, which significantly 
correlated with all the outcome 
measures 
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Model Study Variable  Adjusted 
R Square 
Standard 
error of 
estimate 
F 
change 
p value 
Xe/HT thLac/NAA 0.89 0.14 59.2 <0.001 Stepwise 
MIA thLac/NAA 0.73 0.23 38.1 <0.001 
Table 3.6: Results of multivariable regression model using Tunel density as outcome 
measure and all the EBMs as predictive variables.  
 
Discussion 
We have shown that, by measuring EBMs between 2 and 4 h after hypoxic-ischemic 
insult, MRS predicts the MRS and histo-pathological outcome at 48 hours in control 
animals. Out of all EBMs, thalamic Lac/NAA showed a high significant correlation 
with all possible outcome measures in both studies. Previous studies in neonatal 
piglets showed that 5 of these EBMs (WM and thalamic Lac/Cr and Lac/NAA, and 
Pi/ePP) increased during the 48 hours after HI insult. Four of the biomarkers (WM 
and thalamic NAA/Cr, PCr/ePP, NTP/ePP) decreased, and pH(Pi) first showed a 
moderate early increase (alkalotic shift) by 0.05-0.1 pH points, followed by a 
precipitate drop in case of secondary energy failure (Robertson et al., 2011).  In our 
study, EBMs belonging to the “increasing” group all showed statistically significant 
increase with most outcome parameters (Tunel density, Lac/NAA, Lac/Cr, Pi/EPP), a 
significant decrease with microglial ramification and absence of significant correlation 
for caspase 3. 
 
The course of cerebral Lac after hypoxic-ischemic insult has been well demonstrated 
in experimental studies. Cerebral Lac increases immediately after hypoxia-ischemia, 
and almost normalizes within 30 minutes of starting reperfusion (Lei H and J 1998),  
after which there is a secondary, delayed Lac rise  after several hours (Penrice, 
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Lorek et al. 1997). The immediate Lac production following hypoxia-ischemia is due 
to anaerobic glycolysis in astrocytes stimulated by glutamate excitotoxicity (Pellerin, 
Bouzier-Sore et al. 2007). In addition it is well known that NAA is a neuronal marker, 
and its fall correlates with neuronal death (Sager, Hansen et al. 2000). However, it 
has been shown that fall in NAA after focal ischemia occurs more gradually than 
increase in Lac (Barker P 2005). NAA is synthesized in neuronal mitochondria using 
L-aspartate and acetyl coenzyme A through the reaction of L-aspartateN-
acetyltransferase enzyme. It has been shown that synthesis of NAA as a marker of 
the integrity of neuronal mitochondrial metabolism (Moffett, Ross et al. 2007). There 
is a direct relationship between NAA synthesis, oxygen consumption, and ATP 
production by the mitochondria. Thus high correlation of thalamic Lac/NAA EBM with 
outcome observed in our study may be due to Lac increase rather than fall in NAA. 
However significant correlation of both thalamic and WM NAA/Cr with outcome in 
MIA study (more severe insult), suggests that NAA could start to decrease early if 
there was a severe hypoxia-ischemia.  
 
When ATP generation is impaired, energy flux is maintained by the creatine kinase 
equilibrium with the breakdown of PCr and increase in Pi, so that a decline in PCr 
and increase in Pi  are valuable indicators of impaired energy metabolism even in the 
presence of normal or near normal NTP (mainly NTP). Therefore PCr and Pi gives a 
non-invasive measure of the adequacy of cerebral oxidative metabolism. Several 
studies demonstrated that phosphorus (31P) MRS frequently shows apparently 
normal brain energy metabolism soon after hypoxia-ischemia (Hope, Costello et al. 
1984). However, for infants with eventual adverse outcome, during the first days of 
life PCr and NTP subsequently decline, and Pi increases despite adequate 
resuscitation (Azzopardi, Wyatt et al. 1989, Cady, Amess et al. 1997). This was 
termed as secondary energy failure. The severity of secondary energy failure was 
related to the pathology of hypoxia-ischemia, thus related to outcome in clinical and 
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preclinical studies. Raised Pi/EPP, acquired at 2 h after hypoxia-ischemia, correlated 
with secondary energy failure in our piglet model (Cady, Iwata et al. 2008). Of the 
31P-MRS EBMs, our study revealed that Pi/EPP had the highest correlation with 
outcome, followed by PCr/EPP, and then by NTP/EPP. Pi/EPP had a significant 
correlation with outcome in all forms of injury, but PCr/EPP and NTP/EPP showed 
significant correlation only in severe injury.  
 
One of the important characteristic to be a valid biomarker is to have a strong 
biological basis, which is in the same pathological pathway as the clinical outcome. 
Neuronal cell death following hypoxia-ischemia could be apoptotic or necrotic. The 
most extensively used marker for cell death is based on the integrity of nuclear DNA 
(Wyllie 1980), as DNA degradation indicates irreversible stage of cell death. This 
DNA fragmentation is identified easily and completely by the terminal transferase-
mediated dUTP nick-end labelling (TUNEL) method (Gavrieli, Sherman et al. 1992). 
In addition, activation of microglia has been shown in animal models of excitotoxic 
and hypoxic-ischemic brain injury (Hagberg, Peebles et al. 2002). When activated, 
microglia can take a deramified amoeboid form, thus ramification index could help in 
quantifying the severity of hypoxia-ischemia (Faulkner et al 2011). We observed 
strong and significant correlation of Pi/EPP, thalamic and WM Lac/NAA and Lac/Cr 
with TUNEL detected cell death and microglial ramification index. This demonstrates 
the strong biological association of these EBMs.   
 
As demonstrated in the current meta-analysis based on therapeutic studies for 
combination of Xenon and hypothermia (Faulkner, Bainbridge et al. 2011), and for 
methyl-isobutyl Amiloride, in neonatal piglets (Robertson et al., submitted), EBMs 
acquired with MRS within 2-4h after insult showed a significant correlation with the 
later MRS and histopathology outcome. The extent of correlation was dependent on 
marker, region and insult severity. Increasing EBMs that increased after HI insult 
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(Lac/Cr, Lac/NAA and to some extent Pi/ePP) revealed significant correlation with 
outcome in the control group in the mild to moderate severity insult (Xe/HT). With a 
more severe insult in the MIA study, significant correlation in the control group was 
also observed for decreasing EBMs (NAA/Cr, PCr/ePP, NTP/ePP) even though 
higher R2 values were still observed for the “increasing” group of EBMs. 
 
Conclusion 
In conclusion, early biomarkers, in particular thalamic Lac/NAA, acquired between 2 
and 4 hours after hypoxia-ischemia predicts the MRS and histological outcomes at 
48 hours. The ability to identify hypoxic-ischemic damage and predict the outcome at 
this early time point opens exciting perspectives for future neuroprotective trials. 
These EBMs can be used to select the ideal candidates for such trials. When 
acquired before the onset of treatment, EBMs can reduce the variability of outcome. 
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Chapter 4 -The Predictive Value of late 
MRS Biomarkers (acquired at 40-48 hours 
after HI), in a piglet model of perinatal 
asphyxia 
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Introduction 
Adverse outcomes were observed in up to 50% of cooled infants after therapeutic 
hypothermia (Edwards, Brocklehurst et al. 2010). Hence, research experiments focus 
on the development of adjunct therapies that can improve the efficacy of therapeutic 
hypothermia. Biomarkers, which can act as surrogate end points, are needed to 
speed up such experiments in order to avoid long delay of waiting for long term 
outcome. MRI and MRS can provide such biomarkers. MRI has assessed therapeutic 
hypothermia efficacy in some recent studies (Porter, Counsell et al. 2010, Rutherford, 
Ramenghi et al. 2010) 
A recent meta-analysis of cerebral biomarkers, covering 52 studies and including 860 
babies with NE managed without hypothermia therapy, concluded that early 
conventional MRI ineffectively identified babies at risk of long term adverse outcome 
and that the most accurate predictor was the deep gray matter lactate/N-
acetylaspartate (Lac/NAA) peak-area ratio determined by proton (1H) magnetic 
resonance spectroscopy (MRS) (Thayyil, Chandrasekaran et al. 2010). However, 
currently there have been no studies, which explored the neuroprotective effects on 
the predictive value of these MRS biomarkers.  
 
Our aim was to investigate the 1H and 31P MRS biomarkers, acquired at 40-48 
hours after hypoxia-ischemia, and their correlation to histological outcome in our 
piglet model of HIE. Our aim was also to assess the neuroprotective effects on the 
correlation of MRS biomarkers with cell death.  
Materials and methods 
 
Experiments were carried out according to United Kingdom Home Office guidelines. 
Large-white male piglets, aged < 24h were anesthetised and surgically prepared as 
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described previously (Lorek, Takei et al. 1994, Faulkner, Bainbridge et al. 2011). All 
physiological monitoring and experimental procedures were carried out as explained 
previously (Faulkner, Bainbridge et al. 2011). All data used in the current study were 
from two large translational neuroprotection studies in a piglet model of hypoxic-
ischemia as described in chapters 3 and 4. The first study explored the combination 
of hypothermia and Xenon (Xe/HT)(Faulkner, Bainbridge et al. 2011), the second 
(Robertson et al., in press) the treatment with Methyl-Isobutyl-Amiloride (MIA). MRS 
acquisition and analysis, statistics, histological staining and quantification and 
hypoxia-ischemia were as described in previous chapters. Voxel position and 
representative spectra for naïve and untreated animals after HI at 48 hours are 
shown in figure 4.1.  
 
Analysis of Biomarkers and Outcome data 
 
For biomarkers, we used the MRS data from the final time point, which is acquired 40 
- 48h after completion of HI insults (Table 4.1). These data include 1H MRS WM and 
thalamic voxels (Lac/Cr, NAA/Cr and Lac/NAA), and the whole brain 31P MRS voxel 
(Pi/ePP, PCr/ePP and NTP/ePP). Cho/Cr was not included in the analysis as it 
demonstrated poor correlation with the outcome in our previous study (Faulkner, 
Bainbridge et al. 2011). All these 9 markers are described as MRS biomarkers. 
 
We used MRS data acquired at 48 hours after HI, rather than AUC (which describes 
the change over the course of 48 hours), because of several reasons. Firstly, 48-hour 
data is a single time point data that is not altered by statistical methods. Secondly, 
this data is also not altered by variations that arise due to systemic changes at 
multiple time points. Finally, this is more relevant for clinical translation as it is not 
easy to acquire MRS data on multiple occasions.  
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Experimental 
study  
Group 31P-Whole Brain  
 
Time in hours  
 
Mean + SEM (n) 
 
1H-WM voxel  
 
Time in hours  
 
Mean + SEM (n)  
1H-thalamic voxel  
 
Time in hours  
 
Mean + SEM (n) 
 
Control 47 + 0.23 (8) 42 + 1.1 (8) 42 + 0.67 (8) 
Xenon 47 + 0.41 (8) 45 + 0.77 (8) 44 + 0.76 (8) 
Hypothermia 47.5 + 0.33 (7) 44 + 0.93 (7) 43.5 + 0.76 (7) 
Xe/HT study 
Xe + 
Hypothermia 
46 + 1.0 (8) 43.5 + 1.5 (8) 42.5 + 1.4 (8) 
Control 47 + 0.35 (9) 43 + 0.51 (9) 41.7 + 0.54 (9) MIA study 
MIA 48 + 0.3 (8) 44 + 0.62 (8) 43 + 0.65 (8) 
 
Table 4.1: Acquisition time in hours after HI for the final proton (1H) and phosphorus 
(31P) MRS data acquisition in Xe/HT and MIA experiments. 
 
For outcome, we used histology data; density of TUNEL positive nuclei, density of 
cleaved caspase 3 positive cells, and the ramification index. However, caspase 3 
positive cells demonstrated very poor correlation with our previous studies, and it 
also showed poor correlation with MRS biomarkers on initial analysis in this study. 
Individual histopathology outcomes for each animal and staining were combined by 
using an average across all regions, with the intention to reduce the number of 
outcomes to 2 for each animal. Previous analysis revealed that these averaged 
histopathology values exhibited considerably higher correlation with the biomarker 
AUCs than those observed for region-specific histopathology (Faulkner, Bainbridge 
et al. 2011).  
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Figure 4.1: A: Coronal NMR Image of the piglet showing the location of 
spectroscopy voxels in the dorsal subcortical (dsc) white matter and in ventromedial 
forebrain. B and C: 1H Magnetic resonance spectroscopy in the dorsal subcortical 
voxel in naïve piglet (B) and 48h after a transient, global hypoxic ischemic insult (C). 
Note the massive increase in the lactate peak (Lac) at 1.3ppm and the reduction of 
that for N-Acetyl Aspartate (NAA) at 2ppm. The 3ppm creatine (Cr) peak remains 
largely unchanged. D and E: 31P spectra from a naive piglet (D) and 48 h after 
hypoxia-ischaemia (E). Note the increased inorganic phosphate (Pi) and decreased 
phosphocreatine (PCr), phosphoethanolamine (PET) and c, a and b adenosine 
triphosphate (ATP) in (E). 
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Results 
Five animals from Xenon study and one animal from MIA study died early and so are 
not included in final analysis. In each animal, MRS biomarkers using 1H thalamic 
voxel, 1H WM voxel, and whole brain 31P MRS were acquired serially. 31P MRS-
derived EBMs were obtained between 46 and 48 hours after HI insult, those for the 
1H thalamic voxel at 42 and 44 hours, and for the 1H WM at 42 and 45 hours in 
Xe/HT study. The mean and standard error of the mean for the acquisition time point 
for Xe/HT and MIA studies are shown in table 4.1. There was no significant 
difference in the acquisition time point for all biomarkers between the subgroups in 
both studies.  
 
Effect of Neuroprotection 
The mean values of late biomarkers peak area ratios in both Xe/HT and MIA study 
groups are shown in Table 4.2 and 4.3. There is a significant difference in the values 
between control and treatment groups in both studies (Faulkner, Bainbridge et al. 
2011, Robertson, Kato et al. 2013), representing the effect of treatment. 
Histologicaly, the reduction of Tunel density and caspase positive cells, and increase 
in ramification of microglia are observed in the treated groups of both studies (figure 
4.2 and 4.3) 
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Late 
Biomarkers 
Control 
Mean (SD) 
Xenon 
Mean (SD) 
Hypothermia  
Mean (SD) 
Xe/HT 
 Mean (SD) 
Thalamic 
Lac/NAA 
4.78 (12.4) 0.46 (0.48) 0.28 (0.18) 0.34 (0.52) 
Thalamic 
Lac/Cr 
1.22 (1.30) 0.67 (0.53) 0.51 (0.25) 0.49 (0.48) 
Thalamic 
NAA/Cr 
1.37 (0.58) 1.71 (0.35) 1.93 (0.35) 1.83 (0.36) 
WM Lac/NAA 3.77 (7.4) 0.80 (1.15) 0.50 (0.70) 0.17 (0.07) 
WM Lac/Cr 1.81 (1.56) 0.88 (0.87) 0.78 (0.84) 0.37 (0.09) 
WM NAA/Cr 1.54 (0.82) 1.82 (0.75) 2.28 (0.70) 2.21 (0.49) 
Pi/EPP 0.22 (0.06) 0.20 (0.07) 0.16 (0.06) 0.14 (0.03) 
PCr/EPP 0.27 (0.03) 0.27 (0.04) 0.29 (0.03) 0.31 (0.02) 
NTP/EPP 0.26 (0.02) 0.26 (0.02) 0.28 (0.02) 0.28 (0.01) 
Table 4.2: Mean and standard deviation of late biomarkers peak area ratio of all the 
groups in Xe/HT study.  
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Late Biomarkers 
Control 
Mean (SD) 
MIA  
Mean (SD) 
Thalamic Lac/NAA 59.99(111) 1.59 (2.48) 
Thalamic Lac/Cr 2.92(2.45) 1.27 (1.33) 
Thalamic NAA/Cr 0.82 (0.67) 1.30 (0.46) 
WM Lac/NAA 12.16 (11) 4.9 (5.1) 
WM Lac/Cr 4.77 (3.7) 3.01 (2.17) 
WM NAA/Cr 0.63 (0.04) 0.99 (0.52) 
Pi/EPP 0.57(0.30) 0.40(0.27) 
PCr/EPP 0.13(0.09) 0.19 (0.09) 
NTP/EPP 0.16 (0.11) 0.21 (0.09) 
Table 4.3: Mean and standard deviation of late biomarkers peak area ratio of all the 
groups in MIA study. 
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Figure 4.2: Combination treatment decreases histological damage. Brain histology 
(A-E), TUNEL (F-J) and immunohistochemistry for caspase 3 (K-O, Z-AA) and IBA1 
(P-Y) in naïve, control animals (A,F,K,P,U), 48 hours after untreated hypoxic 
ischemic insult (B,G,L,Q,V), hypothermia (C,H,M,R,W), xenon (D,I,N,S,X) and 
combination of xenon and hypothermia (E,J,O,T,Y). Compared with control animals 
in the left column, the untreated hypoxic ischemic group shows the appearance of a 
large number of eosinophilic, dead neurons (B), many TUNEL-positive (G) and 
caspase immunoreactive neurons (L), and a redistribution of microglial IBA1 
immunoreactivity from a very uniform, diffuse pattern (P) to a retraction from the deep 
subcortical areas and clustering in superficial layer 2 and layer 4 (Q). At high 
magnification, the untreated group (V) shows loss of microglial branching and 
transformation into rounded macrophages. The changes are to a large extent 
reversed following combined treatment, histology in the hypothermia alone and 
xenon alone groups shows an intermediate phenotype.(Z,AA): High magnification of 
cleaved caspase 3 immunoreactivity and haematoxylin counterstain. There are 
numerous neurons with strong cytoplasmic immunoreactivity and pyknotic or 
fragmented nuclei (white arrows), but there also many cells with fragmented or 
pyknotic nuclei without caspase 3 immunoreactivity. Scale bars: A (A-E) - 0.5mm, F 
(F-J) - 0.5mm, K (K-O) - 0.5mm, P (P-T) - 1mm, U (U-Y) - 0.1mm, Z (Z,AA) - 50um 
(magnification for all micrographs for the same row is kept constant). H&E: 
hematoxylin and eosin. Permission to reproduce this figure has been granted by John Wiley and 
Sons 
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Figure 4.3: Methyl isobutyl amiloride (MIA) treatment decreases histological 
damage. Haematoxylin-eosin (H&E) histology (a–c), transferase mediated 
biotinylated d-UTP nick end-labelling (TUNEL) (d–f) and immunohistochemistry for 
caspase 3 (g–i) and ionized calcium- binding adaptor molecule1 (IBA1)(j–o) in naıve 
animals (a,d,g,j,m), and 48 h after hypoxia-ischaemia for placebo (b, e, h, k, n), and 
for post-insult MIA (c, f, i, l, o). Compared with naive (left column), placebo animals 
lost deeper layer neurons on H&E (b), and had a TUNEL+ cell preponderance (e), 
occasional caspase 3 immunoreactive neurons (h, arrows), and a redistribution of 
microglial IBA1 immunoreactivity from a very uniform, diffuse pattern (j) to a 
retraction from deep subcortical areas and large columnar clusters around layer 4 (k, 
arrows). At high magnification, the placebo group (n) also shows loss of microglial 
branching and microglial transformation into rounded macrophages (arrows). The 
cortical changes are to a large extent reversed by MIA, but the hippocampal dentate 
gyrus (hip) appears unaffected. Permission to reproduce this figure has been granted by John 
Wiley and Sons. 
119 
 
Correlation of MRS biomarkers and Histopathology Outcomes for 
untreated animals in the Xe/HT study 
The results of regression analysis between MRS biomarkers and histopathology 
outcome are shown in table 4.4. On regression analysis, all MRS biomarkers showed 
significant correlation with Tunel positive cell death and microglial ramification index. 
WM Lac/Cr showed highest and significant correlation with Tunel cell death (R2– 
0.85, p = 0.003), whereas NTP/EPP (R2– 0.78, p = 0.004) demonstrated highest and 
significant correlation with ramification index. Thalamic and WM Lac/NAA, WM 
NAA/Cr, Pi/EPP and PCr/EPP also demonstrated good significant correlation with 
both outcome measures. However, WM NAA/Cr showed poor correlation with 
ramification index (R2– 0.32, p = 0.14). All correlation graphs were shown in figures 
4.4 and 4.5. 
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Biomarker	   Tunel	  
L	  –
Correlation	  
(R2)	  
p	  -­	  value	   Iba1	  
L	  –
Correlation	  
(R2)	  
p	  -­	  value	  
thLac/NAA 0.54 0.03	   0.67 0.01	  
thLac/Cr 0.68 0.02	   0.49 0.03	  
thNAA/Cr 0.63 0.01	   0.46 0.04	  
wmLac/NAA 0.56 0.03	   0.58 0.02	  
wmLac/Cr 0.85 0.003	   0.71 0.008	  
wmNAA/Cr 0.82 0.002	   0.32 0.140 
Pi/EPP 0.69 0.01	   0.60 0.02	  
Pcr/EPP 0.66 0.01	   0.52 0.04	  
NTP/EPP 0.69 0.01	   0.78 0.004	  
 
Table 4.4: Correlation of late MRS biomarker, acquired at around 48 hours after HI, 
with histological outcome from the control group in Xe/HT study.  
121 
 
 
 
 
Figure 4.4: Correlation between late MRS biomarkers (x axis) and Tunel positive cell 
death (y axis) and their R2 values from control group in Xe/HT study 
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Figure 4.5: Correlation between late MRS biomarkers (x axis) and microglial 
ramification index (y axis) and their R2 values from control group in Xe/HT study 
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Correlation of MRS biomarkers and Histopathology Outcomes for 
untreated animals in the MIA study 
To revalidate the predictive value of MRS biomarkers, the same analysis was done 
using the data from the MIA treatment study in a more severe form of HI insult. All 
MRS biomarkers showed significant correlation with Tunel positive cell death and 
ramification index, as shown in figure 4.6 and 4.7. The results of the regression 
analysis are shown in table 4.5. Similar to Xe/HT study, WM Lac/Cr demonstrated 
highest and positive correlation with Tunel positive cell death (R2– 0.98, p = 0.00) 
and NTP/EPP with microglial ramification (R2– 0.68, p = 0.006). Compared to Xe/HT 
study results, all9 markers showed better correlation for Tunel positive cell death with 
statistical significance (p<0.01); the R2 of 6 out of 9 biomarkers were more than 0.90 
(Table 4.5). Similarly better significant correlation was noted with ramification index. 
However WM NAA/Cr demonstrated less and non-significant correlation with 
ramification index, similar observation as in Xe/HT study.  
124 
 
 
 
Figure 4.6: Correlation between late MRS biomarkers (x axis) and Tunel positive cell 
death (y axis) and their R2 values from control group in MIA study 
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Figure 4.7:  Correlation between late MRS biomarkers (x axis) and microglial 
ramification index (y axis) and their R2 values from control group in MIA study 
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Table 4.5: Correlation of late MRS biomarkers with histological outcome from control 
group in MIA study 
 
Correlation of MRS biomarkers after neuroprotective intervention in 
Xe/HT and MIA studies 
As there was a consistent, significant and positive correlation for most MRS 
biomarkers with histopathology outcomes in the control group, we further analysed 
them in the intervention groups (Xenon, hypothermia and combined Xenon and 
hypothermia) of Xe/HT study and treatment group in MIA study. Table 4.6 shows all 
the correlation values of MRS biomarkers with Tunel positive cell death.  All MRS 
biomarkers showed significant correlation with Tunel positive cell death (Table 4.6). 
WM Lac/NAA showed highest and significant correlation across all treatment groups, 
Biomarker	   Tunel	  
L	  –
Correlation	  
(R2)	  
p	  -­	  value	   Iba1	  
L	  –
Correlation	  
(R2)	  
p	  -­	  value	  
thLac/NAA 0.75 0.01	   0.51 0.07	  
thLac/Cr  
0.96 
	  
<0.001	  
 
0.52 
	  
0.02	  
thNAA/Cr 0.94 <0.001	   0.66 0.008	  
wmLac/NAA 0.95 <0.001	   0.63 0.01	  
wmLac/Cr 0.98 <0.001	   0.49 0.03	  
wmNAA/Cr 0.63 0.01	   0.23 0.18 
Pi/EPP 0.95 <0.001	   0.66 0.007	  
PCr/EPP 0.83 0.002	   0.53 0.02	  
NTP/EPP 0.97 <0.001	   0.68 0.006	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particularly very high correlation for hypothermia group (R2– 0.94, p = 0.001). 
Thalamic Lac/NAA and Lac/Cr, WM Lac/Cr also showed significant correlation with 
Tunel positive cell death, consistently observed in all intervention groups (Figure 4.8). 
Pi/EPP and WM NAA/Cr showed good correlation too. NTP/EPP and PCr/EPP 
demonstrated good correlation in hypothermia and Xenon groups; however, there 
was poor correlation in the combined xenon and hypothermia group. Thalamic 
NAA/Cr showed good correlation in xenon and combined group; however the 
correlation was non-significant in hypothermia and MIA treated groups. All MRS 
biomarkers showed poor and non-significant correlation with microglial ramification 
index across all treatment groups.  
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Figure 4.8: Correlation between late MRS biomarkers (x axis) and Tunel positive cell 
death (y axis) and their R2 values from treatment groups in Xe/HT and MIA studies. 
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Late 
Biomarkers 
Hypothermia 
R2   (p value)   
Xenon 
R2 (p value) 
Xenon + 
Hypothermia 
R2 (p value) 
Amiloride  
R2 (p value) 
thLac/NAA 0.51 (0.02) 0.55 (0.02) 0.62 (0.01) 0.52 (0.01) 
thLac/Cr 0.65 (0.02) 0.63 (0.01) 0.62 (0.01) 0.63 (0.02) 
thNAA/Cr 0.43 (0.05) 0.40 (0.06) 0.70 (0.005) 0.45 (0.01) 
wmLac/NAA 0.94 (0.001) 0.84 (0.01) 0.80 (0.001) 0.74 (0.002) 
wmLac/Cr 0.88 (0.001) 0.81 (0.001) 0.74 (0.01) 0.50 (0.04) 
wmNAA/Cr 0.83 (0.01) 0.61 (0.01) 0.52 (0.02) 0.52 (0.03) 
Pi/EPP 0.59 (0.01) 0.90 (<0.001) 0.59 (0.02) 0.56 (0.02) 
Pcr/EPP 0.27 (0.19) 0.70 (0.009) 0.26 (0.16) 0.64 (0.03) 
NTP/EPP 0.52 (0.04) 0.79 (0.003) 0.03 (0.6) 0.51 (0.01) 
 
Table 4.6: Correlation between late MRS biomarkers and Tunel positive cell death 
from treatment groups in Xe/HT and MIA studies. 
 
Discussion 
This study has shown that all MRS biomarkers, acquired at around 48 hours after 
hypoxic-ischemic insult, demonstrated significant correlation with the histo-
pathological outcomes after HI. It has also shown that this correlation remains even 
after neuroprotective intervention. Out of all the MRS biomarkers, thalamic and WM 
Lac/NAA, thalamic and WM Lac/Cr and Pi/EPP showed a significant correlation with 
histological outcome in both untreated and treated animals in both studies. There are 
not many studies in the literature that correlated Lac/NAA to Tunel density 
representing cell death. The existence of significant correlation of Lac/NNA to 
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histological outcome after therapeutic intervention in animals after HI has not been 
shown before. 
 
This consistently high and significant correlation of thalamic and WM Lac/NAA with 
histological outcome observed in control animals of our study may be due to delayed 
Lac increase and fall in NAA which happens around 48 hours after HI when the MRS 
biomarkers acquired. This significant correlation was also present in treated animals 
those received any form of neuroprotective intervention. Our studies showed that 
neuroprotective treatment ameliorates the cerebral Lac rise and fall in NAA, as well 
as reducing tissue damage (Faulkner, Bainbridge et al. 2011, Robertson, Kato et al. 
2013). Thus thalamic and WM Lac/NAA correlated well with histological cell death. 
This significant correlation combined with treatment effect clearly explains the 
biological basis of late biomarkers, particularly thalamic and WM Lac/NAA.  
 
Of the 31P-MRS, our study revealed that Pi/EPP had the highest correlation with 
outcome, followed by PCr/EPP and NTP/EPP. Pi/EPP had a significant correlation 
with outcome after all intervention in all forms of injury, but PCr/EPP and NTP/EPP 
did not showed significant correlation in combined xenon and hypothermia group.  
 
The results of this study did not change with the severity of injury. In the previous 
chapter, early biomarkers demonstrated differential correlation depending on the 
severity of HI. Increasing EBMs like Lac/NAA, Lac/Cr showed significant correlation 
in moderate and severe injury as in Xe/HT study and MIA study respectively; 
however decreasing EBMs like NAA/Cr, NTP/EPP showed significant correlation only 
in severe injury as in MIA study. This does not hold true with this study, as MRS 
biomarkers, all increasing and decreasing types, acquired at 48 hours showed 
significant correlation with the outcome in moderate and severe injury.  
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Microglia are highly ramified cells in the resting state (Raivich 2005).  When activated 
by ischemia or infection, microglia can take on a deramified, amoeboid phagocytic 
phenotype. Microglia are activated along with neutrophil infiltration, during cerebral 
hypoxia-ischemia and reperfusion (Hudome, Palmer et al. 1997). Activated microglia 
were observed from 4 hours after reperfusion and continued to increase over the 
next 48 hours (Bona, Andersson et al. 1999). An association has been shown 
between the activation, migration and proliferative activity of brain microglia 1-3 days 
after the injury with brain lactate(Garcia JH and Y 1974). Microglial response to injury 
was assessed by the microglial ramification index in this study. From this study, 
increasing biomarkers including Lac/NAA correlated negatively with ramification 
index in control animal and decreasing biomarkers correlated positively with it; 
however none of the biomarkers correlated with ramification index in treated animals. 
This could be due to the fact that microglia were still undergoing the changes of 
activation and proliferation at 48 hours after HI. Although ramification was reversed in 
combined treatment with xenon and hypothermia, there were intermediate changes 
in other intervention groups (Faulkner, Bainbridge et al. 2011). 
 
Therapeutic hypothermia for newborn infants with neonatal encephalopathy has 
taken approximately 15 years to reach the clinical stage in the developed world 
(Edwards 2009). As several promising neuroprotective agents are being tested 
currently (Kelen and Robertson 2010), these therapies need more rapid clinical 
translation, for which robust and sensitive quantitative biomarkers predicting long-
term outcome are required. More importantly, these biomarkers should predict 
outcome after neuroprotective intervention.  
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Conclusion 
 In this study, most MRS peak area ratios, particularly Lac/NAA and Lac/Cr, have 
shown good and significant correlation with the outcome after neuroprotective 
intervention independent of severity of HI. Their prognostic utility should be evaluated 
in newborn infants with HI after neuroprotective intervention (hypothermia). These 
findings provide an excellent opportunity to try these biomarkers as surrogate end 
points on forthcoming clinical trials.  
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Chapter 5 - The predictive value of MRS 
biomarkers after therapeutic hypothermia 
in neonatal infants with NE - Clinical 
Translation 
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Introduction 
Current research focuses on the development, evaluation and deployment of adjunct 
therapies that can enhance the efficacy of therapeutic hypothermia. The associated 
clinical trials are particularly challenging and time consuming, because of necessarily 
large sample sizes and long follow-up delay. Robust biomarkers assessing treatment 
effects and predictive of long term outcome have value as surrogate endpoints for 
phase II randomised control trials of the most promising neuroprotectants and 
minimise the risk of failure in phase III randomised control trials.  
In the previous 2 chapters, it has been shown that early and late MRS biomarkers 
had good significant correlation with short-term outcome following HIE in a piglet 
model with or without neuroprotection. In the present study we used MRI and deep 
gray matter MRS in babies with neonatal encephalopathy (NE) managed with and 
without therapeutic hypothermia to determine whether their predictive accuracies 
were altered by such treatment   
Patients and methods 
We recruited all term babies with NE admitted to the tertiary neonatal unit at 
University College Hospital between October 2006 and September 2009 who had 
MRI and MRS aged 4 to 14 days.  
 
NE was diagnosed by the following criteria; (1) evidence of hypoxia during delivery 
consisting of at least one of: (a) Apgar score <5 10 minutes after birth, (b) continued 
need for resuscitation, including endotracheal or mask ventilation, 10 minutes after 
birth, (c) acidosis within 60 minutes of birth (defined as any umbilical cord, arterial or 
capillary pH <7.00) with base deficit >16mmol/L in any blood sample (arterial, venous 
or capillary); and (2) evidence for encephalopathy, consisting of  abnormal 
consciousness state (lethargy, stupor or coma) and at least one of : hypotonia, 
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abnormal reflexes including oculomotor or pupillary abnormalities, an absent or weak 
suck, or clinical seizures. Figure 5.1 shows the study flow chart. 
 
Mode of delivery, gestational age, sex, birth weight, Apgar score, birth occipitofrontal 
head circumference, hypothermia intervention status, Sarnat NE grading (Sarnat and 
Sarnat 1976) and age at MRI  were recorded. The East and Central London 
Research Ethics Committee approved this study.  
 
MRI and MRS 
MRI and MRS were performed on a 1.5-Tesla Avanto (Siemens, Erlangen, 
Germany).  Imaging used 3D T1–weighted spoiled gradient echo (field of view (FOV) 
210x158 cm, repetition time (TR) 17ms, echo time (TE) 6ms, 1 average, 
0.8x0.8x1mm voxel, acquisition matrix 512x384), 2D T2-weighted fast spin echo 
(axial and coronal sections; FOV 210x158cm, slice thickness 3mm, acquisition matrix 
512x384, 3 averages, TR 6000 ms, TE 110ms) and diffusion tensor imaging spin 
echo EPI sequence  (30 diffusion directions, FOV 230x172.5mm, slice thickness 3 
mm, acquisition matrix 128x96, 1 average, TR 5200 ms, TE 131 ms, b 600 s/mm2). 
Spectroscopy used 1H PRESS (TR 2290 ms, TE 288 ms, 37 summable subspectra 
of 8 averages each, 1.5 x 1.5 x 1.5 cm voxel centred on the left thalamus and 
lentiform nucleus (Figure 5. 2).  Metabolite ratios including Lac/NAA, Lac/total 
creatine (Cr), Lac/choline (Cho), NAA/Cr and NAA/Cho were calculated using LC 
model as previously described (Cheong, Cady et al. 2006).   
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Figure 5.1: Study flow chart 
137 
 
 
All babies had MRI aged 4 to 14 days, and all cooled babies had rewarmed to normal 
temperature beforehand.   MRI and MRS were performed sequentially during natural 
sleep or after sedation with oral chloral hydrate (50 mg/kg) for babies breathing 
spontaneously or with intravenous morphine infusion (10 micrograms/kg/hour) if 
mechanically ventilated. Babies were studied in a protective Perspex pod. For 
immobilization and acoustic noise reduction, the infant’s head was partly surrounded 
by soft padding and both ears were protected with 24-dB attenuation ear plugs 
(Earsoft; Earo, Indianapolis, Ind) and 7-dB attenuation earmuffs (Natus minimuffs, 
Natus Medical Inc., San Carlos, CA). Neonatal intensive care, including mechanical 
ventilation, intravenous fluids, and ionotropic drug administration, was continued as 
appropriate, with heart rate, oxygen saturation, temperature and ECG monitoring.  A 
neonatologist and neonatal nurse were present throughout. 
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Figure 5.2: Thalamic voxel position (transverse plane). Typical MR spectra with 
normal lactate at 1.33ppm for infants with favourable outcome and raised lactate for 
infants with unfavourable outcome.  
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All MRI scans were assessed by a single pediatric neuroradiologist (4 years 
experience) for quality, normal anatomy and acquired lesions. As previously 
described (Miller, Ramaswamy et al. 2005, Rutherford, Ramenghi et al. 2010) MRI 
was classified as abnormal when there was at least one of: moderate or severe 
lesions in the basal ganglia and thalamus, or severe white matter lesions including in 
the watershed area (Figure 5.3). Posterior limb of internal capsule (PLIC) was 
classified abnormal as detailed previously (Rutherford, Ramenghi et al. 2010).  
 
My Role  
I worked as a neuroimaging fellow in the neonatal unit at University College Hospital 
during the study period. I obtained informed consent for MRI from parents. Along with 
a team of advanced neonatal nurse practioners, I stabilised all the babies and shifted 
them safely to the magnet room in a transport incubator, cared for them during the 
scan and transported them back to the unit safely. I also presented the case history 
of infants in the weekly neuro-meeting with a neuro-radiologist where each MRI/MRS 
scan results were reported. I also ensured that all infants were booked for 
neurodevelopmental follow up appointment. I also worked in clinical shifts as a 
registrar (1:9 on-call shift system) where I cared for all neonatal infants. A team of 
physicists helped me to collect MRS data in the study. I analysed all the data using 
appropriate statistical methods, later checked by the statistician.  
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Figure 5.3: T2-weighted MRI abnormalities in NE (transverse plane). . (A) Normal 
deep gray matter including basal ganglia and normal surrounding white matter and 
cortical folds. (B) Increased white-matter signal intensity (arrow) demonstrating 
moderate white matter lesions. (C) Abnormal low signal intensity in basal ganglia and 
thalamus (arrow) demonstrating local deep gray matter injury (D) Severe white 
matter and deep gray matter lesions in severe global hypoxic-ischemic injury. 
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Neurodevelopmental outcome 
All survivors were assessed at age 18 months by a developmental paediatrician (5 
years experience) and an occupational therapist using standard neurologic 
assessment (Amiel-Tison.C 2001) and the Bayley Scales of Infant and Toddler 
Development (Bayley-3). Bayley-3 comprises 5 assessment scales covering 
cognitive, language (including receptive communication and expressive 
communication) and motor (including fine and gross motor) which are combined as a 
single composite score (Bayley 2006). Outcomes were categorised as favourable 
(normal neurologic assessment and composite score ≥80) or unfavourable 
(functional motor deficits and composite score <80 or died due to NE). 
 
Statistical analysis  
We used Predictive Analytics Software 18 (PASW; IBM, USA) for all statistical 
analyses. Intergroup clinical and perinatal characteristics were compared by χ2 for 
categorical data and Mann-Whitney test for continuous data. Predefined threshold 
values based on published literature were used to calculate diagnostic indices 
(Thayyil, Chandrasekaran et al. 2010).The efficacies of MRI and MRS for predicting 
abnormal outcome at age 18 months were compared by calculating their predictive 
accuracies, sensitivities, specificities, and positive and negative predictive values. 
Exact confidence intervals (CI) based on the F distribution were calculated for 
sensitivity, specificity and predictive values. 
For direct comparison of the diagnostic utilities of individual tests, we used diagnostic 
odds ratios (DOR) and area under the curve (AUC). AUC was calculated using 
PASW 18. DOR is the ratio of the odds of positivity with disease relative to that 
without disease and was calculated as described in the literature (Glas, Lijmer et al. 
2003). Univariate analysis assessed relationships between Apgar score, Sarnat NE 
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severity, hypothermia therapy, MRI and MRS results, and motor outcome. Logistic 
regression and calculation of adjusted odds ratios (adjusted OR, 95% CI) examined 
associations between MRI and MRS results and motor outcome including allowance 
for perinatal factors significant on univariate analysis. Two-sided p < 0.05 was 
assumed significant.  
Results 
Forty-nine babies were recruited of which 28 were included for final analysis (Fig.5. 1 
for exclusions and Table 5.1 for included infants’ clinical characteristics).  Eleven 
babies received therapeutic hypothermia (33.5-34oC for 72 h starting within 6 h of 
delivery). Birth weights, birth gestational age, Apgar scores aged 10 min and birth 
head circumferences were similar in both groups.  Median age at MRI/MRS was 7 d 
in uncooled babies and 10 d in cooled. Both groups had equal numbers of infants 
with moderate or severe encephalopathy as assessed by Sarnat grading (Sarnat and 
Sarnat 1976). However, no cooled infants had mild NE whereas 6 uncooled did 
(p=0.01).  
Comparative biomarker prognostic accuracies  
Lac/NAA sensitivities and specificities for predicting adverse outcome were 
respectively 100% (95% CI; 55,100) and 100% (95% CI; 90, 100) in uncooled babies, 
and 100% (95% CI; 57, 100) and 100% (95%; 84, 100) in previously cooled  (Table 
5.2).  However,  MRI sensitivities and specificities were respectively 100% (95% CI; 
48,100) and 71% (95% CI; 60,71) in uncooled  babies and 66%(95% CI; 24, 93) and 
75%(95% CI; 59,85) in previously cooled  (Table 5. 2). Thalamic  Lac/NAA and 
Lac/Cr were the best predictors of unfavourable outcome (Table 5.2).   
The predictive accuracy (AUC) of thalamic Lac/NAA was 0.97 for uncooled and 1.0 
for previously cooled  babies (Table 5. 2): thalamic Lac/Cr predictive accuracies were 
also high in both groups. However, MRI predictive accuracy was worse. The thalamic 
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Lac/NAA DOR was much better than for all other predictors (Table 5.2). Importantly, 
there was no intergroup Lac/NAA difference between favourable and unfavourable 
outcome (Fig 5. 4).  
On univariate analysis, Sarnat NE severity was associated with motor outcome (p = 
0.001). Hence Sarnat grading and hypothermia treatment were included as 
covariates in binomial logistic regression analyses. With and without adjustment for 
Sarnat NE grade and hypothermia treatment logistic regression showed that both 
Lac/NAA and Lac/Cr had similar good predictive accuracy (Table 5.3). Before 
adjustment for Sarnat NE grade and hypothermia, treatment MRI predicted adverse 
outcome:  however, after adjustment, MRI OR was not statistically significant (Table 
5.3). 
Six babies had unfavourable outcome; three of them were cooled (Table 5.4). In the 
uncooled group, two babies had global developmental delay with microcephaly and 
one had severe hemiplegic cerebral palsy (CP). In the cooled group, one baby had 
deafness and gross motor delay, one had hemiplegic CP, and one had spastic CP 
with visual impairment. All uncooled infants with mild NE had normal outcome. All 
babies with unfavourable outcome had raised cerebral Lac/NAA. Although MRI 
correctly identified all uncooled babies with unfavourable outcome, MRI did not 
identify the cooled baby who developed gross motor delay.  
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Table 5.1: Clinical  characteristics (IQR - interquartile range) 
 
 
Characteristics Cooled  (n=11) Uncooled  (n=17)  
 
P value  
Median (IQR) 
gestational age at 
birth (wk)  
40(39.5, 41) 40 (40, 41) 1.0 
Median (IQR) birth  
weight (gm)  
3625(3182, 4365) 3140(2660, 3580) 0.07 
Median (IQR) 
Apgar at 10 min 
5 (3.5, 7.5) 7.4 (7, 9) 0.07 
Median (IQR) head  
circumference (cm)  
36 (35.2, 36.3) 33.9(33, 35.2) 0.12 
Median (IQR) age  
at MRI/MRS (d)   
7(5, 8.5) 10.2 (5, 12) 0.24 
Sex (M:F) 5:6 8:9 0.79 
Sarnat NE stage 
mild (n) 
0 6 0.01 
Sarnat NE 
moderate (n) 
9 7 0.71 
Sarnat NE severe 
(n) 
2 4 0.45 
Infants with 
unfaourable 
outcome (n) 
3 3 0.8 
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Table 5.2: MRI and MRS sensitivities and specificities for unfavourable outcome and 
predictive values, diagnostic odds ratios and AUC. 
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Table 5.3: Biomarker odds ratios and significances from logistic regression analysis 
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Figure 5.4: Thalamic Lac/NAA for favourable and unfavourable outcome (mean and 
95% CI). 
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Case 
ID 
Study 
Group 
Cognitive 
scale 
Language 
scale 
Motor 
scale 
Neurology Examination 
1 N 106 95 90 Normal 
2 N       70 74 65 Global delay and Microcephaly 
3 N 95 121 103 Normal 
4 N 90 74 110 Normal 
5 N 115 138 103 Normal 
6 N 110 74 86 Normal 
7 N 100 109 94 Normal 
8 N 102 95 90 Normal 
9 N 115 118 118 Normal 
10 N 100 127 112 Normal 
11 N 110 102 100 Normal 
12 N 80 72 65 Hemiplegic CP 
13 N 95 83 75 Normal 
14 N 112 95 95 Normal 
15 N 95 91 86 Normal 
16 N 70 79 69 Global delay and Microcephaly 
17 N 100 90 92 Normal 
18 H 
140 112 110 
Normal 
19 H 
105 103 136 
Normal 
20 H 
60 56 58 
Spastic CP with visual problems 
21 H 
120 97 100 
Normal 
22 H 
100 103 97 
Normal 
23 H 
100 100 91 
Normal 
24 H 
80 83 69 
Deafness and motor delay  
25 H 
95 98 110 
Normal 
26 H 
78 70 60 
Hemiplegic CP 
27 H 
110 103 88 
Normal 
28 H 
105 91 112 
Normal 
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Table 5.4: Outcome data as measured at 18 months of age. The Bailey 3 scores and 
neurological examination findings of all infants in both study groups are shown here. 
N - Normothermia, H – Hypothermia.  
 
Discussion 
This paper reports the accuracies of cerebral MRI and MRS biomarkers for predicting 
adverse outcome in infants who received therapeutic hypothermia for NE. Consistent 
with the conclusion of our recent systematic review (Thayyil, Chandrasekaran et al. 
2010), early deep gray matter Lac/NAA was the most accurate predictor of long term 
adverse neurological outcome following NE and Lac/NAA prediction accuracy was 
unaltered by preceding therapeutic hypothermia. The discriminatory power of 
qualitative reporting of conventional MRI and abnormal PLIC was poor.  
To the best of our knowledge, this is the first study to report the prognostic 
accuracies of cerebral MRI and MRS biomarkers in encephalopathic babies who 
have had therapeutic hypothermia. An extensive recent meta-analysis of cerebral 
MRI and MRS biomarkers in  babies who had no hypothermic intervention for NE 
concluded that the most accurate outcome predictor was deep gray matter Lac/NAA 
(Thayyil, Chandrasekaran et al. 2010).  Conventional MRI and PLIC abnormality 
were less prognostic. The results presented in this study from babies who had or did 
not have prior hypothermic treatment are consistent with these findings. Thalamic 
Lac/NAA had 100% specificity in both uncooled and hypothermia pre-treated babies, 
while this ratio had 95% specificity in the meta-analysis in uncooled babies. 
Conventional MRI had 71% specificity in uncooled babies and 75% in hypothermia 
pre-treated babies, while this modality had 51% specificity in the meta-analysis in 
uncooled babies. The diagnostic accuracies of conventional MRI in our study 
(uncooled 0.81, hypothermia pre-treated 0.75) were similar to those in a recently 
published large randomised control study (Rutherford, Ramenghi et al. 2010). 
However, the diagnostic accuracy of thalamic Lac/NAA was always better.   
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It is essential to understand Lac and NAA time-dependences after hypoxia-ischemia, 
and particularly during therapeutic hypothermia. There are characteristic spectrum 
changes in infants with NE, especially Lac elevation (conventionally interpreted as a 
result of brain ischemia and hypoxia), and a fall in NAA (suggestive of neuronal 
injury). However NAA falls slower than Lac rises (Petroff, Ogino et al. 1988, Graham, 
Blamire et al. 1993). From animal studies, we know that cerebral Lac rises during 
hypoxia-ischemia, but normalises after resuscitation and reperfusion (Lei and Peeling 
1998). However, there is a further delayed Lac rise several hours later possibly due 
to renewed Lac production or mitochondrial failure (Penrice, Lorek et al. 1997). This 
rise may persist for considerable time (Hanrahan, Cox et al. 1998). In global ischemia 
in  gerbils, decreased brain NAA correlated with neuronal loss and remaining 
neuronal density (Sager, Topp et al. 2001) In our piglet transient hypoxia-ischemia 
model, the extents of the rise in brain Lac and NAA fall over the first 48 h after 
hypoxia-ischemia are  strongly associated with nuclear DNA fragmentation in dying 
cells detected with – terminal Transferase d-UTP Nick End-Labeling (TUNEL) 
histochemistry (Chandrasekaran M 2010).  
Furthermore, in brain cortex and thalamus, cellular metabolism is temperature 
dependent (Mendelowitsch, Mergner et al. 1998, Jia, Yue et al. 2008). In our piglet 
hypoxia-ischemia model, we monitored cerebral metabolism with MRS every 6 h 
during therapeutic hypothermia and found lessened Lac rise during hypothermia 
(unpublished data).  However, high cortical Lac levels were observed in normal 
Sprague–Dawley rats during mild hypothermia (Chan, Chow et al. 2010). Hence, the 
predictive value of Lac during hypothermia is uncertain.  
An advantage of this study was that the MRI scanners and protocols were the same 
throughout: however, there were limitations. Firstly this is a prospective observational 
study conducted in a single neonatal unit before and after introduction of rescue 
hypothermic neuroprotection as standard care, rather than a randomised control trial. 
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As a result, the NE severity of uncooled babies was dissimilar to that of those who 
were cooled. However, this study's intention was to examine the prognostic 
accuracies of MRI and MRS biomarkers in a cohort resembling very closely that 
expected clinically rather than to examine the treatment effects of hypothermia.  
Secondly, the presented metabolite ratio results are relevant only when exactly the 
same protocols and scanners are used. Hence, caution must be exercised when 
using cerebral MRI and MRS biomarkers as surrogate outcome measures in 
multicentre studies.  Metabolite ratio variance increase of about 10% has been 
reported in multicentre studies using different scanners. Hence, our data may be 
unusable for sample size calculation for multicentre trials of neuroprotective therapies 
employing MRI or MRS as a surrogate outcome measure.  
Finally, as with all previous single-centre studies examining MRI prognostic accuracy, 
our sample size is small and this is reflected in the wide estimate confidence 
intervals. Thus our findings need confirmation in larger cohorts.  
Conclusion 
Prior therapeutic hypothermia did not alter thalamic Lac/NAA or Lac/Cr outcome 
prediction accuracy. Our data show that after moderate therapeutic hypothermia for 
NE in the early neonatal period (age < 2 weeks) thalamic Lac/NAA remains a robust 
biomarker predictive of outcome.  MRS metabolite ratios may be useful surrogate 
biomarkers in future trials of neuroprotective therapies in such infants. 
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Chapter 6 - Conclusion and 
further research 
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The predictive value of Early MRS biomarkers (EBMs), acquired around 
4h after HI, in the piglet asphyxia model 
This study demonstrated that EBMs, acquired between 2h and 4h after a hypoxic-
ischemic insult, predict the evolution of the energy disturbances on MRS and histo-
pathological outcome at 48 hours after HI. Specifically, thalamic Lac/NAA and Lac/Cr 
AUC showed strong association with the outcome in both Xe/HT and MIA 
experimental series.  
From our study, there was a very close correlation between Lac/NAA (acquired early) 
and TUNEL – positive cells. This important finding can be of enormous use to 
research and clinical areas. As several neuroprotective drugs still need to be tested 
in animal experiments, it is essential to standardize the HI insult severity and reduce 
the variability in the outcome. EBMs, particularly Lac/NAA, could play a significant 
role in reducing the variability.  If we could predict the severity of the outcome by 
EBMs, acquired as early as 2-4h after HI (within the therapeutic window), appropriate 
candidates could be selected for neuroprotective intervention in clinical studies. It can 
be difficult and challenging to identify newborn infants who could potentially benefit 
from neuroprotection because of the evolving clinical presentation. Even though the 
therapeutic window for neuroprotective intervention is brief, it is not impossible to 
acquire early MRS biomarkers within the required time. Thus EBMs can be used to 
identify the ideal candidates in order to reduce costs and time spent on these trials.  
Approximately, 25% of encephalopathic infants die in the neonatal period due to the 
severity of the injury and a clinical redirection of care. Clinicians use wide range of 
clinical, electrophysiological (aEEG) and neuroimaging techniques to assess the 
severity of encephalopathy. Even though, there is some evidence for a early aEEG to 
prognosticate long term outcome (Toet, Hellstrom-Westas et al. 1999), the  value of 
early MRI to predict long term outcome is poor (Thayyil, Chandrasekaran et al. 
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2010). It is essential that we offer better counselling to parents regarding outcomes 
and to avoid offering false hope to parents.  EBMs could play a significant role in 
decision making for these infants.  
The predictive value of late MRS biomarkers, acquired around 48h after 
HI, in the piglet asphyxia model 
This study demonstrated that MRS biomarkers, acquired at 48 hours after HI, predict 
the histological outcome in untreated, control animals. This study also has shown 
that neuroprotective intervention did not affect the predictive ability of these 
biomarkers. More specifically, thalamic and WM Lac/NAA and Lac/Cr showed good 
outcome prediction in control animals as well as in animals who received 
neuroprotective intervention in both Xe/HI and MIA experimental series.  
This is an important finding as these MRS biomarkers can be used as surrogate end 
point in future neuroprotective trials. Despite therapeutic hypothermia, up to 50% of 
newborn infants still have abnormal neurological outcome (Edwards, Brocklehurst et 
al. 2010). Currently research is being focused on developing and evaluating several 
neuroprotective adjuncts (Kelen and Robertson 2010). While evaluating these 
neuroprotective drugs, these MRS biomarkers can provide rapid results as outcome 
measures and can help to speed up the translation of these drugs to clinical 
research.   
 
The predictive value of MRS biomarkers in newborn babies with HI - 
Clinical translation of MRS biomarkers 
This study has shown that thalamic Lac/NAA acquired between 4 and 14 days of 
age, predicts long term neurodevelopmental outcome at 18 months of age. This 
study also demonstrated that prior therapeutic hypothermia did not alter thalamic 
Lac/NAA outcome prediction accuracy.  
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This novel finding is a key in validating MRS biomarkers as a clinical outcome 
measure. These studies prove that MRS can be trusted as a bridging biomarker. In 
clinical neuroprotection trials, MRS should be used as a surrogate end point so that 
the results can be obtained earlier to save time and money. This also helps in more 
rapid clinical application of effective neuroprotectants and saving more infants from 
disability.  
Further research  
Optimisation of MRS acquisition 
The presented metabolite ratio results are relevant only when exactly the same 
protocols and scanners are used. Hence, caution must be exercised when using 
cerebral MRI and MRS biomarkers as surrogate outcome measures in multicentre 
studies. Also Lac detection depends on TE of the pulse sequence used. Use of 3T is 
increasing, and optimization and standardization of acquisition methods are needed.  
Absolute quantification of metabolites 
It is well known that NAA is a neuronal marker. In global ischaemia, decreases in 
brain NAA are closely correlated neuronal loss and remaining neuronal 
density(Sager, Topp et al. 2001). Also on secondary analysis of the systematic 
review (Thayyil, Chandrasekaran et al. 2010), the predictive ability of absolute 
quantification of NAA concentration was promising, observed in 2 studies. NAA 
concentrations may therefore be important for monitoring neuroprotective 
interventions in the newborn with perinatal asphyxial encephalopathy. A large 
prospective international study evaluating cerebral MRI biomarkers including 
absolute quantification, as surrogate outcome measures is currently in progress 
(MARBLE study– Magnetic Resonance Biomarkers in Neonatal Encephalopathy; 
Clinical Trials No: NCT01309711). Future animal studies may consider evaluating the 
relationship between absolute concentrations of metabolites with Tunel positive cell 
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death and microglial ramification.  
Long term Follow up 
The predictive value of MRS biomarkers is based on 18 month – 
neurodevelopmental outcome from the current study. However it is essential to follow 
these infants for longer duration, at least up to 5 years to evaluate the full 
neurological impairment. This will ensure the further validation of these biomarkers.  
Predictive value of WM MRS metabolite ratios 
From the results of animal studies as mentioned in previous chapters, WM Lac/NAA 
and other WM metabolite ratios also had good correlation with histological outcome. 
However the predictive value of WM MRS metabolite ratios is not known in newborn 
infants. This should be evaluated in future studies as this might provide great insights 
into cognitive outcome.   
The course of microglial activation after neuroprotective intervention 
As many studies have shown the activation, proliferation and de-ramification of 
microglia following HI, little is known about the microglial course following 
neuroprotective intervention like hypothermia. Although we noticed the preservation 
of ramification to some extent, it is difficult to explain the poor correlation to MRS 
metabolite ratios following neuroprotection. Further studies are needed to analyse 
the course of microglia following neuroprotective intervention.  
MRS metabolite changes during hypothermia 
This study has shown that hypothermia does not affect the predictive accuracy of 
thalamic Lac/NAA and Lac/Cr when acquired after hypothermia treatment. The 
influence of treatments on lactate generation following hypoxia-ischaemia is unknown 
but would be of interest.  
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A limitation in the translation of experimental work to the clinic is that, unlike the 
experimental set-up, in infants with NE, the precise timing of the hypoxia-ischaemia 
is unknown. This study is reassuring, however, as it shows that MRS biomarkers, 
particularly thalamic Lac/NA, are predictive both early (2-4h) and late (48h), making 
knowledge of the timing of the insult less vital.                                                           
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Table 1 
Variables N (n=9) Xe (n=8) Hypo (n=8) 
Xe+Hypo 
(n=7) 
Postnatal age (hr) 23.3 (0.9) 23.3 (0.7) 23.6 (0.7) 23.3 (0.9) 
Body weight (g) 1688 (221) 1719 (365) 1694 (253) 1763 (107) 
Insult severity (hr×10-2) 10.4 (2.5) 11.5 (2.4) 11.7 (4.1) 11.5 (2.4) 
HR (bpm) Baseline 163 (15) 161 (16) 160 (17) 167 (18) 
End of insult 188 (22)a 169 (16) 169 (18) 176 (18) 
2-26 hr after time zero 161 (19) 165 (23) 133 (26)d,e 134 (24)d,e 
48 hr after time zero 129 (12)a 135 (20)a 153 (17)cd 144 (18) 
MABP(mmHg)Baseline 46 (4) 43 (5) 41 (6) 44 (6) 
End of insult 53 (5)a 47 (4) 47 (4) 46 (7) 
2-26 hr after time zero 48 (6) 43 (4)d 40 (6)d 40 (7)d 
26-48 hr after time zero 46 (8) 47 (5) 40 (3) 45 (5) 
T rectal (°C)   Baseline 38.7 (0.4) 39.0 (0.1) 38.8 (0.2) 38.8 (0.4) 
End of insult 38.6 (0.3) 38.5 (0.4) 38.5 (0.2) 38.5 (0.3) 
6-26 hours after time zero 38.6 (0.3) 38.7 (0.3) 33.3 (0.3)a,d,f 33.4 (0.4)a,d,f 
48 hr after time zero 38.5 (0.2) 38.5 (0.3) 38.6 (0.4) 38.9 (0.2) 
PaO2 (kPa)  Baseline 9.7 (1.2) 11.4 (1.8) 10.9(1.2) 10.6 (1.9) 
nadir of the insult 2.9 (0.3)a 4.3 (1.0)ad 2.7 (0.5)a 6.0 (1.2)ade 
24 hr after time zero 13.3 (1.4) 13.0 (1.2) 12.1 (1.2) 14.8 (1.9) 
48 hr after time zero 13.2 (3.4) 18.9 (12.4) 15.1 (4.5) 12.0 (3.5) 
PaCO2 (kPa) Baseline 5.1 (0.9) 6.2 (0.4) 5.9 (1.6) 6.0 (1.3) 
nadir of the insult 5.3 (0.7) 5.0 (0.3)a 4.9 (1.2) 4.6 (1.1)a 
24 hr after time zero 4.7 (2.4) 5.2 (1.9) 4.3 (3.3) 5.6 (1.9) 
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48 hr after time zero 5.5 (1.9) 5.4 (2.2) 3.8 (3.0) 5.8 (1.7) 
pH                  Baseline 7.52 (0.06) 7.46 (0.04) 7.49 (0.09) 7.48 (0.07) 
nadir of the insult 7.42 (0.10)a 7.48 (0.05) 7.47 (0.11) 7.49 (0.07) 
24 hr after time zero 7.47 (0.11) 7.50 (0.15) 7.44 (0.12) 7.45 (0.11) 
48 hr after time zero 7.43 (0.13) 7.44 (0.11) 7.46 (0.11) 7.36 (0.07) 
BE (mmol/L)  Baseline 7.2 (2.7) 8.9 (2.7) 8.6 (2.5) 8.3 (2.4) 
nadir of the insult 1.4 (5.9)a 4.2 (3.4)a 4.2 (4.2)a 4.2 (3.1)a 
24 hr after time zero 6.2 (3.5) 6.7 (5.3) 6.4 (6.3) 5.4 (1.1) 
48 hr after time zero 1.8 (2.9)ac 3.6 (4.6)a 2.7 (2.8)ac 1.6 (2.5)a 
Lactate(mmol/L)Baseline 3.2 (1.9) 2.7 (0.6) 2.5 (0.6) 2.6 (0.7) 
nadir of the insult 7.4 (2.4)a 6.0 (1.4)a 5.5 (1.9)a 6.1 (0.8)a 
24 hr after time zero 1.4 (0.4) 1.9 (0.6) 0.9 (0.3) 1.1 (0.4) 
48 hr after time zero 1.7 (0.7) 1.7 (0.3) 1.4 (0.4) 1.4 (0.5) 
*glucose(mmol/L)Baseline 7.2 (1.0) 7.3 (0.8) 6.9 (1.1) 7.2 (1.7) 
nadir of the insult 9.3 (1.9) 8.6 (1.4) 8.6 (1.8) 10.0 (2.2) 
24 hr after time zero 4.5 (1.3) 4.6 (1.8) 5.2 (0.7) 9.7 (4.6) 
48 hr after time zero 5.1 (0.9) 4.7 (1.1) 4.0 (1.1) 4.9 (0.2) 
 
Table 1. Physiological variables for piglets in each group of Xe/HT study. Mean (SD) 
values are presented for each group. One-way ANOVA and post hoc analysis was 
carried out on comparisons between groups with Bonferroni correction for repeated 
measures.  Time zero was set at the start of resuscitation after insult (HI).Insult 
severity index was defined as the time integral of the acute energy depletion (AED) 
during HI and for 60mins of resuscitation. a: p<0.05 within group comparisons vs 
baseline; b: p<0.01; c: p<0.05 within group comparisons vs 24h after time zero; d: 
p<0.01 vs normothermia at the same time point or during the same time period;  e: 
p<0.01 vs Xe at the same time point or during the same time period;  f: p<0.05 vs Xe 
at the same time point. * insufficient data points to complete statistical analysis. 
Permission to reproduce this table has been granted by John Wiley and Sons. 
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Table 2 
Variables Time MIA Group  
Mean (SD) 
Placebo Group  
Mean (SD) 
p value (MIA 
vs Placebo) 
Number of 
piglets 
 n=9 n=9  
Postnatal age 
(h) 
 21.9 (13-
26.5) 
23.4 (21.5-28) 0.47 
Bodyweight (g)  1870 (220) 1830 (190) 0.74 
Insult severity 
(10-2h) 
 11.6 (1.4) 12.9 (3.0) 0.25 
Rectal  Baseline 38.2 (0.5) 38.4 (0.4) 0.32 
Temperature HI end 38.7 (0.7) 38.6 (0.7) 0.67 
(°C) 2.5-26h   38.7 (0.5)* 38.6 (0.2) 0.39 
 26.5-48h   38.5 (0.3) 38.5 (0.2) 0.91 
Heart rate  Baseline 177 (27) 195 (19) 0.13 
(min-1) HI end 152 (27)* 194 (21)   0.002 
 2.5-26h   147 (15)* 183 (13) <0.001 
 26.5-48h   130 (15)* 162 (13)* <0.001 
MABP  Baseline 47 (9) 45 (6) 0.67 
(mmHg) HI end 45 (6) 44 (4) 0.60 
 2.5-26h   46 (5) 45 (6) 0.57 
 26.5-48h   48 (7) 46 (7) 0.44 
Isoflurane (%)  Baseline 2.7 (0.5) 2.7 (0.3) 0.95 
 HI end 2.1 (0.0) - (°) 
 2.5-26h   2.4 (0.2) 2.4 (0.5) 0.77 
 26.5-48h  2.3 (0.3) 2.1 (0.6) 0.30 
FiO2 (%) Baseline 32 (6) 33 (3) 0.71 
 HI end 35 (6) 52 (0)  
 2.5-26h  33 (17) 35 (9) 0.75 
 26.5-48h   35 (4) 51 (13) 0.07 
Blood pH Baseline 7.46 (0.08) 7.46 (0.08) 0.94 
 HI end 7.44 (0.01) 7.39 (0.01) (°) 
 2.5-26h   7.46 (0.08) 7.49 (0.10) 0.54 
 26.5-48h   7.45 (0.07) 7.38 (0.20) 0.36 
PaCO2 (kPa) Baseline 6.0 (1.3) 5.5 (1.4) 0.48 
 HI end 5.9 (0.4) 6.8 (0.0) (°) 
 2.5-26h   5.6 (1.2) 5.1 (1.4) 0.47 
 26.5-48h  5.3 (1.3) 5.6 (1.2) 0.62 
PaO2 (kPa) Baseline 8.8 (1.6) 9.2 (1.7) 0.62 
 HI end 10.5 (3.0) 13.2 (1.6) (°) 
 2.5-26h   13.2 (3.7)* 13.4 (3.1)* 0.89 
 26.5-48h   15.0 (1.7)* 13.8 (2.1)* 0.26 
Base excess 
(mmol/L) 
Baseline 6.9 (1.9) 4.3 (2.5) 0.02 
 HI end 5.5 (0.7) 5.0 (0.4) (°) 
 2.5-26h   4.9 (3.1) 4.7 (5.0) 0.90 
 26.5-48h   2.4 (3.2) 2.1 (4.8) 0.87 
Blood Sodium Baseline 141 (6) 139 (3) 0.28 
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(mmol/L) 
 HI end 141 (11) 139 (0) (°) 
 2.5-26h   136 (4)* 135 (3)* 0.52 
 26.5-48h  I 133 (9)* 133 (6)* 0.89 
     
Blood 
Potassium 
(mmol/L) 
Baseline 4.0 (0.8) 4.1 (1.0) 0.81 
 HI end 3.8 (1.8) 4.6 (0.6) (°) 
 2.5-26h   5.1 (1.4)* 5.1 (1.0)* 0.99 
 26.5-48h   5.6 (1.3)* 5.0 (1.5) 0.39 
Blood Lactate Baseline 2.5 (0.9) 3.6 (1.4) 0.06 
(mmol/L) HI end 2.5 (1.2) 2.5 (0.0) (°) 
 2.5-26h  1.7 (1.0)* 1.9 (0.7)* 0.66 
 26.5-48h   1.5 (0.5)* 1.3 (0.7)* 0.55 
 
Table 2. Physiological variables for piglets in the MIA study. Measurements were 
made at baseline and during 3 time periods: 0.5-2h post HI (HI end), 2.5-26h post HI, 
and 26.5-48h post HI. Each variable was averaged over each time period for each 
animal. Intergroup comparisons used the unpaired t test (right column). *p<0.05 
against baseline value in the same group (MIA treated or placebo) using paired t-test. 
° Insufficient data for statistical testing. There were no differences between groups at 
baseline apart from a slightly more alkaline blood pH in the MIA group. There were 
no physiological and serum electrolyte or biochemical differences between groups 
following HI apart from a lower heart rate in the MIA group. Permission to reproduce this 
figure has been granted by John Wiley and Sons.  
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